Press Releases

 
Press Releases
  Date Title View
Jan 12, 2018
BERKELEY, Calif., Jan. 12, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on January 10, 2018 the Compensation Committee of Dynavax's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 57,000 shares of common stock to six new employees. These awards were gran...
Jan 8, 2018
BERKELEY, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] is now available in the United States for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. HEPLISAV...
Jan 4, 2018
BERKELEY, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that Eddie Gray, Dynavax's chief executive officer, will present at the J.P. Morgan 36th Annual Healthcare Conference next week in San Francisco, CA. The presentation will be webcast live and will occur on Thursday, January 11, 2018 ...
Dec 5, 2017
BERKELEY, CA -- (Marketwired) -- 12/05/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that on November 28, 2017 the Compensation Committee of Dynavax's Board of Directors approved (i) the grant of inducement stock options to purchase an aggregate 73,800 shares of common stock and (ii) an inducement restricted stock unit award...
Nov 27, 2017
BERKELEY, CA -- (Marketwired) -- 11/27/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Eddie Gray, Dynavax's chief executive officer, will present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference this week in Boston, MA. The presentation will be webcast live and will occur on Thursday, November 30, 2017 at 2:2...
Nov 9, 2017
BERKELEY, CA -- (Marketwired) -- 11/09/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. HEPLIS...
Nov 3, 2017
BERKELEY, CA -- (Marketwired) -- 11/03/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2017. Cash, cash equivalents and marketable securities were $191.7 million at September 30, 2017 compared to $81.4 million at December 31, 2016. The increase was primarily due to ne...
Oct 19, 2017
BERKELEY, CA -- (Marketwired) -- 10/19/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced initiation of dosing in a phase 1B dose escalation clinical trial of its investigational inhaled toll-like receptor 9 (TLR9) agonist, DV281, in patients with non-small cell lung cancer (NSCLC). This multi-center, open label trial is designed to e...
Sep 5, 2017
BERKELEY, CA -- (Marketwired) -- 09/05/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the company will present at two upcoming investor conferences in September. NewsMakers in the Biotech Industry Investor ConferenceFriday, September 8, 2017 in New York at 8:30 a.m. Eastern Time ...
Aug 15, 2017
BERKELEY, CA -- (Marketwired) -- 08/15/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the completion of an underwritten public offering of 5,750,000 shares of its common stock, including 750,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares wer...
Aug 9, 2017
BERKELEY, CA -- (Marketwired) -- 08/09/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of a previously announced underwritten public offering of 5,000,000 shares of its common stock, offered at a price to the public of $15.00 per share. The gross proceeds to Dynavax from this offering are expected to be approximat...
Aug 8, 2017
BERKELEY, CA -- (Marketwired) -- 08/08/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it intends to offer and sell $125.0 million of shares of its common stock, subject to market and other conditions, in an underwritten public offering. Dynavax also expects to grant the underwriters a 30-day option to purchase up to an a...
Aug 3, 2017
BERKELEY, CA -- (Marketwired) -- 08/03/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has requested more detailed information about the company's proposed post-marketing study for HEPLISAV-B™ [Hepatitis B Vaccine, Recombinant (Adjuvanted)] based on feedback received from...
Aug 2, 2017
BERKELEY, CA -- (Marketwired) -- 08/02/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2017. Cash, cash equivalents and marketable securities were $127.0 million at June 30, 2017 compared to $81.4 million at December 31, 2016. The increase was primarily due to net proceed...
Jul 28, 2017
BERKELEY, CA -- (Marketwired) -- 07/28/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 12 to 1 that the safety data for HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] support licensure for...
Jun 2, 2017
BERKELEY, CA -- (Marketwired) -- 06/02/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced the presentation of findings in patients with metastatic melanoma in the dose escalation phase of an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-P...
May 19, 2017
BERKELEY, CA -- (Marketwired) -- 05/19/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that updated data from an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy developed by Merck (known as MSD outside the United States...
May 8, 2017
BERKELEY, CA -- (Marketwired) -- 05/08/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2017. Cash, cash equivalents and marketable securities were $85.4 million at March 31, 2017 compared to $81.4 million at December 31, 2016. The increase was primarily due to net proceeds...
Apr 3, 2017
BERKELEY, CA -- (Marketwired) -- 04/03/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the U.S. Food and Drug Administration (FDA) has informed the company that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) will review HEPLISAV-B™ [Hepatitis B Vaccine, Recombinant (Adjuvanted)] at its mee...
Mar 20, 2017
BERKELEY, CA -- (Marketwired) -- 03/20/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will be presenting data on three programs based on stimulation of the immune response using Toll-Like Receptor 9 (TLR9) agonists at the 2017 American Association for Cancer Research Annual Meeting in Washington, D.C. from April 1-5,...
Mar 13, 2017
BERKELEY, CA -- (Marketwired) -- 03/13/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2016. The net loss for the year ended December 31, 2016 was $112.4 million, or $2.92 per share, compared to $106.8 million, or $3.25 per share, for the year ended Decemb...
Mar 6, 2017
BERKELEY, CA -- (Marketwired) -- 03/06/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced the presentation of findings in patients with metastatic melanoma in the dose escalation phase of an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-P...
Mar 2, 2017
BERKELEY, CA -- (Marketwired) -- 03/02/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Eddie Gray, Dynavax's chief executive officer, will present at the Cowen and Company 37th Annual Health Care Conference next week in Boston, MA. The presentation will be webcast live and will occur on Monday, March 6, 2017 at 1:20 p.m....
Feb 28, 2017
BERKELEY, CA -- (Marketwired) -- 02/28/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Dynavax's responses to the Complete Response Letter (CRL) issued by the FDA in November 2016 for the Biologics License Application for HEPLISAV-B, the company's vaccin...
Feb 16, 2017
BERKELEY, CA -- (Marketwired) -- 02/16/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Michael Ostrach, Dynavax's senior vice president and chief financial officer, will present at the 2017 RBC Capital Markets Global Healthcare Conference next week in New York, NY. The presentation will be webcast live and will occur on ...
Jan 9, 2017
BERKELEY, CA -- (Marketwired) -- 01/09/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that Eddie Gray, Dynavax's chief executive officer, will present at the J.P. Morgan 35th Annual Healthcare Conference this week in San Francisco, CA. The presentation will be webcast live and will occur on Thursday, January 12, 2016 at 8:30...
Jan 5, 2017
BERKELEY, CA -- (Marketwired) -- 01/05/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX), a clinical-stage biopharmaceutical company, today announced that it is reshaping its strategy and operations to prioritize its emerging clinical and preclinical immuno-oncology portfolio. The company has implemented significant organizational restructurin...
Dec 5, 2016
BERKELEY, CA -- (Marketwired) -- 12/05/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced clinical data from an ongoing Phase 1/2, two-part clinical trial evaluating intratumoral administration of SD-101 in the treatment of low-grade lymphoma. The combination of intratumoral SD-101 and low-dose irradiation resulted in tumor regr...
Dec 1, 2016
BERKELEY, CA -- (Marketwired) -- 12/01/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the company will hold a Research and Development (R&D) Day in New York City next week where it will showcase its immuno-oncology program. The event, which is for institutional investors, will be webcast live and can be found in the Inv...
Nov 30, 2016
BERKELEY, CA -- (Marketwired) -- 11/30/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present clinical data from a Phase 1/2 clinical trial evaluating its immuno-oncology product, SD-101, in patients with low-grade, B cell lymphoma. The poster presentation will be made at the 58th American Society of Hematology (...
Nov 14, 2016
BERKELEY, CA -- (Marketwired) -- 11/14/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for HEPLISAV-B™ [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for immunization ...
Nov 9, 2016
BERKELEY, CA -- (Marketwired) -- 11/09/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced the presentation of findings from an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. Early results investigating 13 patients with m...
Nov 7, 2016
BERKELEY, CA -- (Marketwired) -- 11/07/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter and nine months ended September 30, 2016. The Company had $109.6 million in cash, cash equivalents and marketable securities as of September 30, 2016, compared to $196.1 million at December 31...
Oct 27, 2016
BERKELEY, CA -- (Marketwired) -- 10/27/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has entered into a note purchase agreement with one or more funds of Deerfield Management Company, L.P, pursuant to which Dynavax has agreed to sell, and Deerfield has agreed to purchase, $100 million principal amount of Dynavax's 1...
Oct 26, 2016
BERKELEY, CA -- (Marketwired) -- 10/26/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced sub-group results from HBV-23, the pivotal Phase 3 trial of its investigational hepatitis B vaccine HEPLISAV-B™ [Hepatitis B Vaccine, Recombinant (Adjuvanted)]. The new subgroup analysis demonstrated that HEPLISAV-B, when administere...
Oct 9, 2016
BERKELEY, CA -- (Marketwired) -- 10/09/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced the first presentation of findings from an ongoing Phase 1/2 study evaluating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with Keytruda ® (pembrolizumab), Merck's anti-PD-1 treatment. Early results evaluating five patients wi...
Sep 4, 2016
BERKELEY, CA -- (Marketwired) -- 09/04/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research has cancelled the scheduled November 16, 2016, Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting to review the Biolog...
Aug 5, 2016
BERKELEY, CA -- (Marketwired) -- 08/05/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter and six months ended June 30, 2016. The Company had $139.0 million in cash, cash equivalents and marketable securities as of June 30, 2016, compared to $196.1 million at December 31, 2015. Th...
Aug 5, 2016
BERKELEY, CA -- (Marketwired) -- 08/05/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the Vaccines and Related Biological Products Advisory Committee (VBRPAC) will review the Biologics License Application (BLA) for HEPLISAV-B™ [Hepatitis B Vaccine, Recombinant (Adjuvanted)] at its meeting on November 16, 2016. The...
Jun 11, 2016
BERKELEY, CA -- (Marketwired) -- 06/11/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced preliminary results from a pivotal Phase 3 trial demonstrating that HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] provided a significantly higher rate of seroprotection than Engerix-B®, an approved hepatitis B vaccine, in a...
May 18, 2016
BERKELEY, CA -- (Marketwired) -- 05/18/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present at two upcoming investor conferences. Information relating to the two presentations follows: 2016 UBS Global Healthcare Conference Michael Ostrach, Dynavax's senior vice pre...
May 9, 2016
BERKELEY, CA -- (Marketwired) -- 05/09/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2016. The Company had $166.8 million in cash, cash equivalents and marketable securities as of March 31, 2016, compared to $196.1 million at December 31, 2015. The net lo...
Apr 27, 2016
BERKELEY, CA -- (Marketwired) -- 04/27/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the Biologics License Application (BLA) for HEPLISAV-B™, Dynavax's investigational vaccine for immunization of adults agains...
Apr 18, 2016
BERKELEY, CA -- (Marketwired) -- 04/18/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced encouraging additional data from Part 1 of a Phase 1/2 study (LYM-01) evaluating the company's lead immunotherapy product candidate, SD-101, in combination with low-dose radiation in lymphoma patients. The data were presented at the A...
Apr 18, 2016
BERKELEY, CA -- (Marketwired) -- 04/18/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced results from HBV-23, a pivotal Phase 3 trial that provides head-to-head safety and immunogenicity data comparing its investigational adult hepatitis B vaccine, HEPLISAV-B, with the leading vaccine, Engerix-B, in adults 18 to 70 years ...
Apr 4, 2016
BERKELEY, CA -- (Marketwired) -- 04/04/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present HEPLISAV-B pivotal Phase 3 data at the National Foundation for Infectious Diseases' 19th Annual Conference on Vaccine Research (ACVR). The Conference will take place in Baltimore, Maryland from April 18th throu...
Mar 30, 2016
BERKELEY, CA -- (Marketwired) -- 03/30/16 --  Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for HEPLISAV-B™, the company's vaccine candidate for immunization against hepatitis B infection in adults 18 years...
Mar 17, 2016
BERKELEY, CA -- (Marketwired) -- 03/17/16 --  Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present data at the American Association for Cancer Research Annual Meeting next month in New Orleans, Louisiana. The details for the poster presentations are as follows: Date and Time: Monday, April...
Mar 8, 2016
BERKELEY, CA -- (Marketwired) -- 03/08/16 --  Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2015. The Company had $196.1 million in cash, cash equivalents and marketable securities as of December 31, 2015. Total revenues for the year ende...
Mar 2, 2016
BERKELEY, CA -- (Marketwired) -- 03/02/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that Eddie Gray, Dynavax's chief executive officer, will present at the Cowen and Company 36th Annual Health Care Conference next week in Boston, MA. The presentation will be webcast live and will occur on Wednesday, March 9, 2016 at ...
Feb 17, 2016
BERKELEY, CA -- (Marketwired) -- 02/17/16 --  Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that Eddie Gray, Dynavax's chief executive officer, will participate in a fireside chat at the RBC Capital Markets 2016 Global Healthcare Conference next week in New York, NY. The session will be webcast live and will occur on Wednes...
Jan 19, 2016
BERKELEY, CA -- (Marketwired) -- 01/19/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Company and AstraZeneca signed an amendment to their existing Research Collaboration and License Agreement under which, based on the strategic priorities of the two companies, AstraZeneca will now conduct a Phase 2a safety an...
Jan 11, 2016
BERKELEY, CA -- (Marketwired) -- 01/11/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the company will present at the J.P. Morgan 34th Annual Healthcare Conference this week in San Francisco, CA. The presentation will be webcast live and will occur on Thursday, January 14, 2016 at 10:30 a.m. PT. The live ...
Jan 7, 2016
BERKELEY, CA -- (Marketwired) -- 01/07/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported preliminary top-line results from HBV-23, a Phase 3 trial of the safety and immunogenicity of its investigational hepatitis B vaccine, HEPLISAV-B, compared with a currently marketed vaccine, Engerix-B® , in adults 18 to 70 years ...
Jan 6, 2016
BERKELEY, CA -- (Marketwired) -- 01/06/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) will host a conference call and webcast tomorrow morning, January 7, 2016, at 8:30 a.m. EST. Management looks forward to reviewing top-line clinical data from its Phase 3 HEPLISAV-B trial, HBV-23. To access the conference call by phone, plea...
Dec 5, 2015
BERKELEY, CA -- (Marketwired) -- 12/05/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced clinical data from an ongoing Phase 1/2 clinical trial evaluating intratumoral administration of SD-101 in the treatment of low-grade lymphoma. The combination of intratumoral SD-101 and low-dose irradiation resulted in tumor regression ...
Nov 30, 2015
BERKELEY, CA -- (Marketwired) -- 11/30/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present clinical data at the 57th American Society of Hematology (ASH) Annual Meeting this weekend in Orlando, Florida. The details for the poster presentation are as follows: Date and Time: Saturday, December 5, ...
Nov 5, 2015
BERKELEY, CA -- (Marketwired) -- 11/05/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2015. The Company had $220.7 million in cash, cash equivalents and marketable securities as of September 30, 2015, compared to $93.4 million at June 30, 2015. The bal...
Oct 8, 2015
BERKELEY, CA -- (Marketwired) -- 10/08/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has initiated patient dosing in the company's trial evaluating the combination of two immunotherapies: Dynavax's SD-101 and Merck's (NYSE: MRK) KEYTRUDA® (pembrolizumab). The multicenter, open-label trial is enrolling patie...
Sep 3, 2015
BERKELEY, CA -- (Marketwired) -- 09/03/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the company will participate in two investor conferences next week. Dynavax's presentation at the Newsmakers in the Biotech Industry Conference will occur in New York City on September 10, 2015 at 8:30 a.m. EDT. This presentation w...
Aug 7, 2015
BERKELEY, CA -- (Marketwired) -- 08/07/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2015. The Company had $93.4 million in cash, cash equivalents and marketable securities as of June 30, 2015, compared to $97.6 million at March 31, 2015. The cash, cash e...
Jul 28, 2015
BERKELEY, CA -- (Marketwired) -- 07/28/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the completion of an underwritten public offering of 5,227,273 shares of its common stock, including 681,818 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares...
Jul 22, 2015
BERKELEY, CA -- (Marketwired) -- 07/22/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of a previously announced underwritten public offering of 4,545,455 shares of its common stock, offered at a price to the public of $27.50 per share. The gross proceeds to Dynavax from this offering are expected to be approx...
Jul 21, 2015
BERKELEY, CA -- (Marketwired) -- 07/21/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. Dynavax also expects to grant the underwriters a 30-day option to purchase additional shares of co...
Jul 9, 2015
BERKELEY, CA -- (Marketwired) -- 07/09/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the independent Data and Safety Monitoring Board (DSMB) charged with periodically reviewing safety data from HBV-23, the ongoing Phase 3 clinical study of HEPLISAV-B, Dynavax's investigational adult hepatitis B vaccine, has complet...
Jun 9, 2015
BERKELEY, CA -- (Marketwired) -- 06/09/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that Michael Ostrach, the Company's Chief Financial Officer, will present at the William Blair 35th Annual Growth Stock Conference on Thursday, June 11, 2015 at 8:00 AM Central Time at the Four Seasons Hotel in Chicago. A liv...
Jun 1, 2015
Studies to Evaluate the Combination of Dynavax's SD-101 with Two Immunotherapies from Merck's Pipeline, KEYTRUDA® (pembrolizumab) and MK-1966 Collaboration Includes First-in-human Study for MK-1966, a New Investigational Anti-interleukin-10 (anti-IL-10) Immunomodulator from Merck's R...
May 7, 2015
BERKELEY, CA -- (Marketwired) -- 05/07/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2015. The Company had $97.6 million in cash, cash equivalents and marketable securities as of March 31, 2015, compared to $122.7 million at December 31, 2014. Operating ex...
Mar 5, 2015
BERKELEY, CA -- (Marketwired) -- 03/05/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2014. The Company had $122.7 million in cash, cash equivalents and marketable securities as of December 31, 2014. Loss from operations of $91.3 million for th...
Mar 2, 2015
BERKELEY, CA -- (Marketwired) -- 03/02/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the independent Data and Safety Monitoring Board (DSMB) charged with periodically reviewing safety data from the ongoing phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine, has completed its second ...
Feb 27, 2015
BERKELEY, CA -- (Marketwired) -- 02/27/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that Eddie Gray, the Company's Chief Executive Officer, will present at the Cowen and Company 35th Annual Health Care Conference on Monday, March 2, 2015 at 1:30 PM Eastern Time at the Boston Marriott Copley Place Hotel in Boston. ...
Feb 19, 2015
BERKELEY, CA -- (Marketwired) -- 02/19/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that Eddie Grey, the Company's Chief Executive Officer, will present at the 2015 RBC Capital Markets' Global Healthcare Conference on Tuesday, February 24, 2015 at 9:30 AM Eastern Time at the New York Palace Hotel in New York City. ...
Feb 6, 2015
BERKELEY, CA -- (Marketwired) -- 02/06/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the appointment of Laura Brege to its Board of Directors and Audit Committee. Denise Gilbert, a director and the Chair of the Audit Committee since 2004, will retire from her positions with the company following the next Audit Committee...
Jan 12, 2015
BERKELEY, CA -- (Marketwired) -- 01/12/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2015 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time). Eddie Gray, Chief Executive Officer of Dynavax, wil...
Dec 29, 2014
BERKELEY, CA -- (Marketwired) -- 12/29/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Company has entered into a credit facility with Hercules Technology Growth Capital, Inc. (NYSE: HTGC) for up to $40 million of total funding. Dynavax drew the first tranche of $10 million on closing and has access to an additio...
Dec 9, 2014
BERKELEY, CA -- (Marketwired) -- 12/09/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Company will host a live webcast in conjunction with its Research and Development (R&D) Day on Thursday, December 11, 2014 in New York City. This event for institutional investors will focus on Dynavax's leadership in the applic...
Dec 8, 2014
BERKELEY, CA -- (Marketwired) -- 12/08/14 -- Dynavax Technologies Corp. (NASDAQ: DVAX) today announced that the Company and AstraZeneca AB ("AstraZeneca") signed an amendment to the existing Research Collaboration and License Agreement under which AstraZeneca will fully fund and Dynavax will conduct a Phase 2a safety and efficacy trial of AZD1...
Nov 28, 2014
BERKELEY, CA -- (Marketwired) -- 11/28/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has regained full rights to DV1179, an investigational bifunctional inhibitor of toll-like receptors (TLR) 7 and 9. This resulted from the expiration of the Research and Development Collaboration and License Agreement with GSK o...
Nov 10, 2014
BERKELEY, CA -- (Marketwired) -- 11/10/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the independent Data and Safety Monitoring Board (DSMB) charged with periodically reviewing safety data from the ongoing phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine, has completed its first p...
Nov 7, 2014
BERKELEY, CA -- (Marketwired) -- 11/07/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it had completed a one-for-ten reverse split of its common stock, effective as of 5:00 pm Eastern Time today. Beginning with the opening of trading on November 10, 2014 the Company's common stock will trade on the NASDAQ Capital Ma...
Nov 5, 2014
BERKELEY, CA -- (Marketwired) -- 11/05/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2014. Dynavax had $130.6 million in cash, cash equivalents and marketable securities as of September 30, 2014, compared to $154.3 million at June 30, 2014. The net l...
Oct 13, 2014
BERKELEY, CA -- (Marketwired) -- 10/13/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced initiation of a phase 1/2 clinical trial to assess the safety and preliminary efficacy of SD-101, an investigational Toll-like receptor ("TLR") 9 agonist, in adults with untreated low-grade B-cell lymphoma. In this multicenter study (kn...
Oct 7, 2014
BERKELEY, CA -- (Marketwired) -- 10/07/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Dino Dina, M.D, has resigned from the Board of Directors. Dr. Dina was a director of the Company since 1997 and was the Company's Chief Executive Officer between 1998 and 2013. "We are grateful for Dino's leadership and...
Sep 22, 2014
BERKELEY, CA -- (Marketwired) -- 09/22/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced completion of planned enrollment in the ongoing phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine. More than 8,250 adults, including over 1,100 diabetic subjects, have been enrolled at 40 sites in the U....
Aug 7, 2014
BERKELEY, CA -- (Marketwired) -- 08/07/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2014 and pharmacodynamic and safety results from clinical studies of its asthma drug candidate partnered with AstraZeneca and its systemic lupus erythematosus (SLE) drug candidate p...
Jun 9, 2014
BERKELEY, CA -- (Marketwired) -- 06/09/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the William Blair 2014 Growth Stock Conference in Chicago on Wednesday, June 11, 2014 at 2:40 p.m. Central Time (12:40 p.m. Pacific Time). Eddie Gray, Chief Executive Officer of Dynavax, will provide a...
Jun 2, 2014
BERKELEY, CA -- (Marketwired) -- 06/02/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the Jefferies Global Healthcare Conference in New York on Thursday, June 5, 2014 at 2:30 p.m. Eastern Time (11:30 a.m. Pacific Time). Michael Ostrach, Chief Business and Principal Financial Officer of ...
May 5, 2014
BERKELEY, CA -- (Marketwired) -- 05/05/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2014. The Company had $177.7 million in cash, cash equivalents and marketable securities as of March 31, 2014. For the quarter ended March 31, 2014, Dynavax reported total...
Apr 15, 2014
BERKELEY, CA -- (Marketwired) -- 04/15/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced initiation of a new phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine. This large safety and immunogenicity study (known as HBV-23) was designed to address the Complete Response Letter regarding the HEPL...
Mar 10, 2014
BERKELEY, CA -- (Marketwired) -- 03/10/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2013. The Company had $189.4 million in cash, cash equivalents and marketable securities as of December 31, 2013. For the quarter ended December 31, 2013, Dyn...
Mar 3, 2014
BERKELEY, CA -- (Marketwired) -- 03/03/14 -- Dynavax Technologies Corp. (NASDAQ: DVAX) today announced a $5.4 million milestone payment from its collaborator, AstraZeneca. The companies also amended their research collaboration and license agreement to transfer responsibility for conduct of further clinical trials from Dynavax to AstraZeneca, f...
Feb 28, 2014
BERKELEY, CA -- (Marketwired) -- 02/28/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the 34th Annual Cowen & Company Health Care Conference in Boston on Tuesday, March 4, 2014 at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time). Eddie Gray, Chief Executive Officer of Dynavax, will prov...
Feb 18, 2014
BERKELEY, CA -- (Marketwired) -- 02/18/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it has withdrawn the European Marketing Authorization Application (MAA) for HEPLISAV, its investigational hepatitis B vaccine. The Day 180 List of Outstanding Issues provided by the European Medicines Agency (EMA) indicated that the...
Jan 10, 2014
BERKELEY, CA -- (Marketwired) -- 01/10/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2014 at 9:30 a.m. Pacific Time (12:30 p.m. Eastern Time). Eddie Gray, Chief Executive Officer of Dynavax, will...
Dec 19, 2013
BERKELEY, CA -- (Marketwired) -- 12/19/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) confirmed today that during the fourth quarter of 2013 it had submitted its responses to the Day 120 List of Questions issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding Dynavax's Marketin...
Nov 27, 2013
BERKELEY, CA -- (Marketwired) -- 11/27/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that J. Tyler Martin, M.D. plans to resign from the Board of Directors, effective at the end of the year. Dr. Martin, a director of the Company since 2010, decided to resign to devote more time to his other professional responsibilities. ...
Nov 7, 2013
BERKELEY, CA -- (Marketwired) -- 11/07/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2013. The Company had $76.5 million in cash, cash equivalents and marketable securities as of September 30, 2013, compared to $125.1 million at December 31, 2012. For ...
Oct 25, 2013
BERKELEY, CA -- (Marketwired) -- 10/25/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of previously announced concurrent, separate underwritten offerings of (i) 79,570,000 shares of its common stock at a price to the public of $1.075, for expected gross proceeds of $85.5 million and (ii) 43,430 shares of its S...
Oct 24, 2013
BERKELEY, CA -- (Marketwired) -- 10/24/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it intends to concurrently offer to sell, subject to market and other conditions: (i) shares of its common stock in an underwritten public offering, and (ii) shares of its Series B Convertible Preferred Stock ("Series B") in a separ...
Oct 16, 2013
BERKELEY, CA -- (Marketwired) -- 10/16/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the design of its next large-scale clinical study of HEPLISAV, its investigational adult hepatitis B vaccine, following discussions with the U.S. Food and Drug Administration (FDA or Agency). The planned study, HBV-23, is intended to prov...
Oct 9, 2013
BERKELEY, CA -- (Marketwired) -- 10/09/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the start of dosing in the first human clinical trial in its asthma program. Dynavax is conducting the trial under its collaboration agreement with AstraZeneca. The Phase 1 study will assess the safety of AZD1419, a proprietary TLR9 agon...
Sep 24, 2013
BERKELEY, CA -- (Marketwired) -- 09/24/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that immunogenicity and safety results of two Phase 3 trials (HBV-16 and HBV-17) of HEPLISAV™ investigational hepatitis B vaccine were published in the journal VACCINE accompanied by a Commentary from Drs. Stanley Plotkin and Willia...
Jul 29, 2013
BERKELEY, CA -- (Marketwired) -- 07/29/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2013. The Company had $89.2 million in cash, cash equivalents and marketable securities as of June 30, 2013. This compared to $125.1 million at December 31, 2012. For the...
Jul 11, 2013
BERKELEY, CA -- (Marketwired) -- 07/11/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the appointment of Dr. Robert Janssen, M.D. as Chief Medical Officer and Vice President, Clinical Development. Dr. Janssen most recently served as Dynavax's Vice President, Medical Affairs since November 2012 and was previously Senior Di...
Jul 8, 2013
BERKELEY, CA -- (Marketwired) -- 07/08/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the appointment of Natale ("Nat") Ricciardi to its Board of Directors. Mr. Ricciardi spent his entire 39-year biopharmaceutical career at Pfizer Inc, retiring in 2011 as a member of the Pfizer Executive Leadership Team after holding the ...
Jul 2, 2013
BERKELEY, CA -- (Marketwired) -- 07/02/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the JMP Securities Healthcare Conference in New York on Wednesday, July 10 at 9:00 a.m. EDT (6:00 a.m. PDT). Michael Ostrach, Chief Business Officer of Dynavax, will provide a corporate overview presen...
Jun 19, 2013
BERKELEY, CA -- (Marketwired) -- 06/19/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the 2013 Novartis Prize for Basic Immunology has been awarded to Dr. Robert L. Coffman, Chief Scientific Officer of Dynavax, and his former collaborator Dr. Tim R. Mossman for their groundbreaking research defining subsets of immune...
Jun 11, 2013
BERKELEY, CA -- (Marketwired) -- 06/11/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the William Blair 33rd Annual Growth Stock Conference in Chicago on Tuesday, June 11, at 10:10 a.m. EDT (7:10 a.m. PDT). Michael Ostrach, Chief Business Officer of Dynavax, will provide a corporate ove...
Jun 10, 2013
BERKELEY, CA -- (Marketwired) -- 06/10/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported that it recently concluded a meeting with the U.S. Food and Drug Administration (FDA or Agency) regarding its Biologic License Application (BLA) for HEPLISAV, an investigational adult hepatitis B vaccine. The meeting followed recommendati...
May 6, 2013
BERKELEY, CA -- (Marketwired) -- 05/06/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2013. The Company had $105.4 million in cash, cash equivalents and marketable securities as of March 31, 2013. This compared to $125.1 million at December 31, 2012. For t...
Apr 30, 2013
BERKELEY, CA -- (Marketwired) -- 04/30/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Company's board of directors has appointed Eddie Gray chief executive officer and a member of Dynavax's board, effective May 1, 2013. Mr. Gray will succeed Dino Dina, M.D., Chief Executive Officer. Dr. Dina will remain a consulta...
Mar 21, 2013
BERKELEY, CA -- (Marketwire) -- 03/21/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the appointment of David Novack to the position of Senior Vice President, Operations and Quality, effective March 25, 2013. Mr. Novack brings nearly 25 years of industry experience in manufacturing and supply chain operations, implementin...
Mar 1, 2013
BERKELEY, CA -- (Marketwire) -- 03/01/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2012. The Company had $125.1 million in cash, cash equivalents and marketable securities as of December 31, 2012, following the fourth quarter repayment of a $15 million ...
Feb 26, 2013
BERKELEY, CA -- (Marketwire) -- 02/26/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the Cowen and Company 33rd Annual Healthcare Conference in Boston on Tuesday, March 5, 2013 at 8:40 a.m. Eastern Time (5:40 a.m. Pacific Time). Dino Dina, M.D., Chief Executive Officer of Dynavax, wi...
Feb 25, 2013
BERKELEY, CA -- (Marketwire) -- 02/25/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA or Agency) regarding its Biologic License Application (BLA) for HEPLISAV, an investigational adult hepatitis B vaccine. In th...
Dec 17, 2012
BERKELEY, CA -- (Marketwire) -- 12/17/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 7, 2013 at 6:00 p.m. Eastern Time (3:00 p.m. Pacific Time). Dino Dina, M.D., Chief Executive Officer of Dynavax, ...
Nov 15, 2012
BERKELEY, CA -- (Marketwire) -- 11/15/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (Committee) voted 13 to one that HEPLISAV data adequately demonstrated immunogenicity. Additionally, the Committee voted eight to...
Nov 1, 2012
BERKELEY, CA -- (Marketwire) -- 11/01/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2012. The Company had $148.3 million in cash, cash equivalents and marketable securities as of September 30, 2012. Total revenues for the quarter ended September 30...
Oct 31, 2012
BERKELEY, CA -- (Marketwire) -- 10/31/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into Phase 1 clinical studies. Development expenses will be fully funded by AstraZeneca under the terms of a collaboration announced in 2006, and Dyna...
Aug 28, 2012
BERKELEY, CA -- (Marketwire) -- 08/28/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that its Vaccines and Related Biological Products Advisory Committee (VRBPAC) is scheduled to discuss HEPLISAV at its meeting on November 14-15, 2012. Dynavax's Bio...
Aug 22, 2012
BERKELEY, CA -- (Marketwire) -- 08/22/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for HEPLISAV, pursuing an indication for immunization against infection caused by all known subtypes of hepatitis B virus in...
Aug 13, 2012
BERKELEY, CA -- (Marketwire) -- 08/13/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the appointment of Christine Larson to the position of Vice President and Chief Financial Officer, a newly created position. Ms. Larson brings nearly 25 years of experience as a financial professional to the role, including a background i...
Aug 1, 2012
BERKELEY, CA -- (Marketwire) -- 08/01/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2012. The Company had $160.2 million in cash, cash equivalents and marketable securities as of June 30, 2012 as compared to $114.0 million at December 31, 2011. Total cash for the sec...
Jul 24, 2012
BERKELEY, CA -- (Marketwire) -- 07/24/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) pursuing an indication for immunization against infection caused by all known subtypes of hepatitis B virus in adults 18 through 70 y...
Jul 10, 2012
BERKELEY, CA -- (Marketwire) -- 07/10/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the appointment of David Happel to the position of Vice President of Global Sales and Marketing. Mr. Happel has more than 25 years of experience in the biotech and pharmaceutical industry, including senior level leadership roles in globa...
Jul 9, 2012
BERKELEY, CA -- (Marketwire) -- 07/09/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the 7th Annual JMP Securities Healthcare Conference in New York on Thursday, July 12, at 10:00 a.m. EDT (7:00 a.m. PDT). Tyler Martin, M.D., President and Chief Medical Officer of Dynavax, will ...
Jul 2, 2012
BERKELEY, CA -- (Marketwire) -- 07/02/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the American Medical Association (AMA) Current Procedural Terminology (CPT) Panel has established a CPT code for an adult 2 dose hepatitis B vaccination schedule. HEPLISAV™ will be reported using the new code, differentiating ...
Jun 26, 2012
BERKELEY, CA -- (Marketwire) -- 06/26/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Food and Drug Administration (FDA) has accepted for review the U.S. Biologics License Application (BLA) for HEPLISAV, pursuing an indication for immunization against infection caused by all known subtypes of hepatitis B virus in ...
May 29, 2012
BERKELEY, CA -- (Marketwire) -- 05/29/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the Jefferies 2012 Global Healthcare Conference in New York on Tuesday, June 5, at 9:30 a.m. EDT (6:30 a.m. PDT). Dino Dina, M.D., Chief Executive Officer of Dynavax, will provide a corporate ov...
May 9, 2012
BERKELEY, CA -- (Marketwire) -- 05/09/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of an underwritten public offering of 17,500,000 shares of its common stock, offered at a price to the public of $4.25 per share. The gross proceeds to Dynavax from this offering are expected to be approximately $74.4 million...
May 8, 2012
BERKELEY, CA -- (Marketwire) -- 05/08/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. Dynavax also expects to grant the underwriters a 30-day option to purchase additional shares of its...
May 8, 2012
BERKELEY, CA -- (Marketwire) -- 05/08/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today, that following the recent submission of the U.S. Biologics License Application (BLA) to the Food and Drug Administration (FDA), it intends to begin developing a commercial operation capable of independently launching HEPLISAV™ in ...
Apr 27, 2012
BERKELEY, CA -- (Marketwire) -- 04/27/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2012, including $106.9 million in cash, cash equivalents and marketable securities at March 31, 2012. This compared to $114 million at December 31, 2011. Total cash for the first qua...
Apr 26, 2012
BERKELEY, CA -- (Marketwire) -- 04/26/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has submitted a U.S. Biologics License Application (BLA) to the Food and Drug Administration (FDA) for HEPLISAV, pursuing an indication for immunization against infection caused by all known subtypes of hepatitis B virus in adult...
Mar 27, 2012
BERKELEY, CA -- (Marketwire) -- 03/27/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced final data from a pivotal Phase 3 trial in patients with chronic kidney disease (CKD) demonstrating early seroprotection and the durability of the immune response to HEPLISAV compared to Engerix-B®. In October 2011, Dynavax reported...
Mar 13, 2012
BERKELEY, CA -- (MARKET WIRE) -- 03/13/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that results of an early Phase 3 trial (HBV-04) of HEPLISAV™ investigational hepatitis B vaccine were published online in the journal VACCINE. The article concludes that HEPLISAV was well-tolerated and demonstrated superior and mo...
Mar 6, 2012
BERKELEY, CA -- (MARKET WIRE) -- 03/06/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2011. Dynavax reported $114 million in cash, cash equivalents and marketable securities, cumulatively referred to as total cash, at December 31, 2011. Th...
Feb 14, 2012
BERKELEY, CA -- (MARKET WIRE) -- 02/14/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Dino Dina, M.D., Chief Executive Officer, will be presenting at the Citigroup 2012 Global Health Care Conference to be held February 27-29, and at the Cowen and Company 32nd Annual Health Care Conference being held March 5-7, 2012....
Feb 13, 2012
BERKELEY, CA -- (MARKET WIRE) -- 02/13/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that results of a pivotal Phase 3 trial of HEPLISAV (HBV-10) were published online in the journal VACCINE. Data from this study will be used to support the HEPLISAV Biologics License Application (BLA) submission for an indication in adu...
Feb 2, 2012
BERKELEY, CA -- (MARKET WIRE) -- 02/02/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it met with the Food and Drug Administration (FDA) in a Pre-Biologics License Application (pre-BLA) meeting, and Dynavax and the FDA have agreed that the initial HEPLISAV BLA submission will be for an indication in healthy adults 1...
Dec 21, 2011
BERKELEY, CA -- (MARKET WIRE) -- 12/21/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) and AstraZeneca announced today their decision to advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into IND-enabling preclinical toxicology studies. These toxicology studies are scheduled to be the first module of work perform...
Dec 20, 2011
BERKELEY, CA -- (MARKETWIRE) -- 12/20/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the initiation of a proof-of-mechanism clinical trial of the TLR7 and TLR9 inhibitor, DV1179, in systemic lupus erythematosus (SLE) patients. Initiation of this trial entitles Dynavax to receive a $6 million milestone payment from GlaxoSm...
Nov 8, 2011
BERKELEY, CA -- (MARKET WIRE) -- 11/08/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the completion of a public offering of 27,600,000 shares of its common stock, including 3,600,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. All of the shares were offere...
Nov 3, 2011
BERKELEY, CA -- (MARKET WIRE) -- 11/03/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of a previously announced underwritten public offering of 24,000,000 shares of its common stock, offered at a price to the public of $2.50 per share. The gross proceeds to Dynavax from this offering are expected to be $60 mi...
Nov 2, 2011
BERKELEY, CA -- (MARKET WIRE) -- 11/02/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. Dynavax also expects to grant the underwriters a 30-day option to purchase additional shares of co...
Oct 27, 2011
BERKELEY, CA -- (MARKET WIRE) -- 10/27/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today said that the U.S. Food and Drug Administration (FDA) had concurred with the company's plan to submit a Biologics License Application (BLA) for HEPLISAV for persons over 40 years of age, followed by a supplemental BLA for licensure of a specific ...
Oct 27, 2011
BERKELEY, CA -- (MARKET WIRE) -- 10/27/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2011, including $53.2 million in cash, cash equivalents and marketable securities at September 30, 2011. This amount does not include a total of $8.6 million, consisting of $6 mi...
Oct 27, 2011
BERKELEY, CA -- (MARKET WIRE) -- 10/27/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the company has unblinded its Phase 3 primary endpoint immunogenicity data in subjects with chronic kidney disease and that the data achieved statistical significance demonstrating both the superiority and non-inferiority of HEPLISA...
Oct 25, 2011
BERKELEY, CA -- (MARKET WIRE) -- 10/25/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today highlighted data from two phase 3 studies of its investigational vaccine HEPLISAV™, one of which was the first clinical trial to prospectively evaluate the effectiveness of vaccinations with recombinant hepatitis B vaccines in patients diag...
Oct 21, 2011
BERKELEY, CA -- (MARKET WIRE) -- 10/21/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the expansion of its worldwide strategic alliance with GlaxoSmithKline (GSK) focused on toll-like receptor (TLR) inhibitors. The addition of a new target, TLR8, entitles Dynavax to receive a $3 million milestone payment from GSK. Subjec...
Oct 14, 2011
BERKELEY, CA -- (MARKET WIRE) -- 10/14/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the NewsMakers in the Biotech Industry Conference in New York on Friday, October 21, 2011 at 10:00 a.m. EDT (7:00 a.m. PDT). Dino Dina, M.D., Chief Executive Officer of Dynavax, will provide a ...
Oct 12, 2011
BERKELEY, CA -- (MARKET WIRE) -- 10/12/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will webcast its 2011 Analyst & Investor Day on Thursday, October 27, 2011, from 8:00 - 11:00 a.m. Eastern Time. Presentations and discussions by outside experts and the management team will focus on how Dynavax p...
Oct 10, 2011
BERKELEY, CA -- (MARKET WIRE) -- 10/10/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced immunogenicity data for subpopulations known to be hypo-responsive (males, obese, and smokers) to currently licensed hepatitis B vaccines from its Phase 3 trial (HBV-16). The Phase 3 study was a multi-center, observer-blinded study to d...
Oct 6, 2011
BERKELEY, CA -- (MARKET WIRE) -- 10/06/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the results of a prospective analysis of the diabetic subset population from its Phase 3 trial (HBV-16), showing the superiority of HEPLISAV vs. Engerix-B®, at all measured time points. The modified intent to treat (MITT) analysis ...
Oct 5, 2011
BERKELEY, CA -- (MARKET WIRE) -- 10/05/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) and AstraZeneca have amended their existing Collaboration Agreement to accelerate the initiation of clinical development of AZD 1419, a proprietary second-generation TLR-9 agonist for asthma. Dynavax will manage the early clinical development on behalf ...
Oct 3, 2011
BERKELEY, CA -- (MARKET WIRE) -- 10/03/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) presented yesterday at the 5th Global Vaccine Congress in Seattle, WA an analysis of the modified intent to treat population from its Phase 3 trial (HBV-16), showing the superiority of HEPLISAV vs. Engerix-B®. The previously reported per protocol ...
Sep 18, 2011
BERKELEY, CA -- (MARKET WIRE) -- 09/18/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago, IL presented complete results for the entire study population of its Phase 3 trial (HBV-16). The Phase 3 study, HBV-16, was a multi-center, observer-...
Sep 16, 2011
BERKELEY, CA -- (MARKET WIRE) -- 09/16/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that on Sunday, September 18, at 11:30 am CDT at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), the company will present additional immunogenicity data from its Phase 3 trial (HBV-16) evaluating the im...
Sep 16, 2011
BERKELEY, CA -- (MARKET WIRE) -- 09/16/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the UBS Global Life Sciences Conference in New York on Tuesday, September 20, 2011 at 3:30 pm EDT (12:30 pm PDT). Michael S. Ostrach, Vice President and Chief Business Officer of Dynavax, will p...
Sep 7, 2011
BERKELEY, CA -- (MARKET WIRE) -- 09/07/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the receipt of a two-year Small Business Innovation Research grant (SBIR) for $600,000. The Award is provided by the National Institute of Allergy and Infectious Diseases and will be used to fund research to characterize the role of the...
Sep 1, 2011
BERKELEY, CA -- (MARKET WIRE) -- 09/01/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at William Blair & Company's 2011 Life Sciences Conference in New York on Wednesday, September 7, 2011 at 2:40 pm EDT (11:40 am PDT). Dino Dina, M.D., Chief Executive Officer of Dynavax, will prov...
Aug 11, 2011
BERKELEY, CA -- (MARKET WIRE) -- 08/11/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the Wedbush 2011 Life Sciences Conference in New York on Wednesday, August 17, 2011 at 10:00 am EDT (1:00 pm PDT). Brant Biehn, Chief Commercial Officer of Dynavax, and Shari Annes, Investor Re...
Jul 28, 2011
BERKELEY, CA -- (MARKET WIRE) -- 07/28/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) advised the company that "CBER agrees that clinical consistency of three consecutively manufactured lots of HEPLISAV has been de...
Jul 20, 2011
BERKELEY, CA -- (MARKET WIRE) -- 07/20/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today said that top-line data from its Phase 3 trial comparing HEPLISAV, an investigational hepatitis B virus (HBV) vaccine, to a currently marketed HBV vaccine, Engerix-B, demonstrated non-inferiority, superiority and the safety of HEPLISAV. The study ...
Jul 20, 2011
BERKELEY, CA -- (MARKET WIRE) -- 07/20/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2011. Cash, cash equivalents and marketable securities were $61.7 million at June 30, 2011, compared to $53.2 million at March 31, 2011 and $72.2 million at December 31, 2010. Durin...
Jul 19, 2011
BERKELEY, CA -- (MARKET WIRE) -- 07/19/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) said it will host a conference call and webcast tomorrow, Wednesday, July 20, 2011, to discuss topline Phase 3 data and its second quarter 2011 financial results at 9:00 a.m. Eastern Daylight Time / 6:00 a.m. Pacific Daylight Time. To joi...
Jun 6, 2011
BERKELEY, CA -- (MARKET WIRE) -- 06/06/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the Jefferies 2011 Global Healthcare Conference in New York on Wednesday, June 8, 2011 at 9:30 am EDT (6:30 am PDT). Dino Dina, M.D., Chief Executive Officer of Dynavax, will provide a corporat...
May 25, 2011
BERKELEY, CA -- (MARKET WIRE) -- 05/25/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported completing the 12-month follow-up on all of the 2,449 subjects enrolled in its large-scale Phase 3 study of HEPLISAV™ evaluating immunogenicity in comparison to Engerix, lot-to-lot consistency and safety. With the study's completio...
May 5, 2011
BERKELEY, CA -- (MARKET WIRE) -- 05/05/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2011, including $53.2 million in cash, cash equivalents and marketable securities at March 31, 2011. A $6 million milestone payment from GlaxoSmithKline earned after the close of th...
Apr 20, 2011
BERKELEY, CA -- (MARKET WIRE) -- 04/20/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the start of dosing in the first human clinical trial in its lupus program. Initiation of this trial entitles Dynavax to receive a $6 million milestone payment from GlaxoSmithKline (GSK), its partner in a worldwide strategic alliance. G...
Mar 8, 2011
BERKELEY, CA -- (MARKET WIRE) -- 03/08/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2010. Dynavax reported $72.2 million in cash, cash equivalents and marketable securities at December 31, 2010. This compared to $36.7 million at Dec...
Mar 3, 2011
BERKELEY, CA -- (MARKET WIRE) -- 03/03/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the Cowen and Company 31st Annual Health Care Conference in Boston on Tuesday, March 8, 2011 at 9:30 am EST (6:30 am PST) at the Boston Marriott Copley Place. Dino Dina, M.D., Chief Executive O...
Feb 23, 2011
BERKELEY, CA -- (MARKET WIRE) -- 02/23/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Data Safety Monitoring Board (DSMB) established for Dynavax's two ongoing Phase 3 trials for HEPLISAV™ has completed its planned safety assessments. The DSMB determined that the studies may continue without protocol modification...
Feb 22, 2011
BERKELEY, CA -- (MARKET WIRE) -- 02/22/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) reported in a poster session Saturday, February 19 at the 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2011) in Bangkok, Thailand new Phase 1b immunogenicity data for DV-601, its proprietary hepatitis B therapeutic...
Feb 22, 2011
BERKELEY, CA -- (MARKET WIRE) -- 02/22/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) reported last Friday, February 18 in Geneva, Switzerland at the World Health Organization 7th Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials new Phase 1a and Phase 1b safety and immunogenicity data for its universal f...
Jan 10, 2011
BERKELEY, CA -- (MARKET WIRE) -- 01/10/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced completing the enrollment of its Phase 3 study of HEPLISAV™, Dynavax's novel vaccine for the prevention of hepatitis B infection, in subjects with chronic kidney disease. The multi-center study, conducted in the U.S., Germany and in Can...
Dec 23, 2010
BERKELEY, CA -- (MARKET WIRE) -- 12/23/10 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported safety and immunogenicity data from its Phase 1b clinical trial of DV-601, its proprietary hepatitis B therapeutic vaccine. The dose escalation study assessed safety and the immunologic and virologic responses in 14 subjects with chronic ...
Dec 7, 2010
BERKELEY, CA -- (MARKET WIRE) -- 12/07/10 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported safety and immunogenicity data from its Phase 1a clinical trial of N8295, one of two key components of its Universal Flu Vaccine candidate. N8295 is a fusion protein comprised of NP and M2e, two highly conserved influenza antigens covale...
Nov 29, 2010
BERKELEY, CA -- (MARKET WIRE) -- 11/29/10 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported in the JOURNAL OF EXPERIMENTAL MEDICINE (JEM) new data that suggests an important role of the key innate immune receptors TLR7 and TLR9 in cutaneous lupus and related skin conditions. In the issue of JEM (Volume 207, Number 13), which was...
Nov 12, 2010
BERKELEY, CA -- (MARKET WIRE) -- 11/12/10 -- Dynavax Technologies Corporation (NASDAQ: DVAX) reported that the Company's independent compensation committee approved the granting of equity awards to 11 new employees under the Company's 2010 Employment Inducement Award Plan ("the 2010 Plan") as a material inducement for each individual to become ...
Nov 4, 2010
BERKELEY, CA -- (MARKET WIRE) -- 11/04/10 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2010, including $47.2 million in cash, cash equivalents and marketable securities. This compared to $57.4 million at June 30, 2010. In November 2010, the Company receive...
Nov 2, 2010
BERKELEY, CA, Nov 02, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the completion of a public offering of 26,450,000 shares of its common stock, including 3,450,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. All of the s...
Nov 1, 2010
BERKELEY, CA, Nov 01, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the Oppenheimer 21st Annual Healthcare Conference on Tuesday, November 2, 2010 at 10:15 am EDT (7:15 am PDT) at the Waldorf Astoria Hotel in New York. Michael Ostrach, Chief Business Offi...
Oct 28, 2010
BERKELEY, CA, Oct 28, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of an underwritten public offering of 23,000,000 shares of its common stock at a price to the public of $1.70 per share. The gross proceeds to Dynavax from this offering are expected to be approximately $39....
Oct 27, 2010
BERKELEY, CA, Oct 27, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as sole book-running manager of the offering. Wedbush PacGrow Life Sciences and Cowen ...
Oct 21, 2010
BERKELEY, CA, Oct 21, 2010 (MARKETWIRE via COMTEX News Network) -- In a late-breaker oral presentation on October 23, 2010 at the Annual Meeting of the Infectious Diseases Society of America (IDSA) in Vancouver, British Columbia, Dynavax Technologies Corporation (NASDAQ: DVAX) will report that its novel hepatitis B vaccine candidate, HEPLISAV(TM), ...
Oct 21, 2010
BERKELEY, CA, Oct 21, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will webcast its first Analyst & Investor Day on Friday, October 29, 2010, from 8:00 - 11:00 am Eastern Time. Presentation and discussions will focus on hepatitis B: epidemiology, unmet needs, and public/ind...
Oct 20, 2010
BERKELEY, CA, Oct 20, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the BioCentury NewsMakers in the Biotech Industry conference on Friday, October 22, 2010 at the Millennium Hotel in New York City, NY. Michael Ostrach, Chief Business Officer, will provid...
Oct 11, 2010
BERKELEY, CA, Oct 11, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today said that Dr. William L. Heyward, Vice President, Clinical Development, will make an oral presentation of new data from a subset of diabetes subjects evaluated as part of the company's previously reported multicenter, observer-bl...
Oct 4, 2010
BERKELEY, CA, Oct 04, 2010 (MARKETWIRE via COMTEX News Network) -- In an abstract published today on the website of the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Dynavax Technologies Corporation (NASDAQ: DVAX) reported that its novel hepatitis B vaccine candidate, HEPLISAV(TM), given as two doses over ...
Sep 28, 2010
BERKELEY, CA, Sep 28, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Data Safety Monitoring Board (DSMB) established for Dynavax's two ongoing Phase 3 trials for HEPLISAV(TM) has completed the third of its planned safety assessments. The DSMB determined that the studies may cont...
Sep 23, 2010
BERKELEY, CA, Sep 23, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has begun to immunize subjects in a Phase 1b clinical trial of its Universal Flu Vaccine candidate. The study will evaluate the safety of the combination of N8295, the novel component of Dynavax's Universal Flu ...
Sep 20, 2010
BERKELEY, CA, Sep 20, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Aspire Capital Fund, LLC, an Illinois limited liability company, has purchased 1,000,000 shares of Dynavax common stock at $2.00 per share, representing a 23% premium to the closing market price on September 17, 20...
Sep 16, 2010
BERKELEY, CA, Sep 16, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that its Chief Business Officer, Michael Ostrach, plans to make a formal presentation at UBS Global Life Sciences Conference 2010 on Monday, September 20, 2010 at 2:00 pm Eastern Time (11:00 am Pacific Time) at the Gran...
Aug 31, 2010
BERKELEY, CA, Aug 31, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today a grant from the National Institute of Allergy and Infectious Diseases (NIAID) to take a systems biology approach to study the differences between individuals that do or do not respond to vaccination against the Hepatit...
Jul 30, 2010
BERKELEY, CA, Jul 30, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2010, including $57.4 million in cash and cash equivalents. This compared to $30.1 million at March 31, 2010. In April, the Company completed a financing which resu...
Jul 29, 2010
BERKELEY, CA, Jul 29, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the Wedbush Life Sciences Best Ideas Conference 2010 on Tuesday, August 3, 2010 at 8:00 am Eastern Time (5:00 am Pacific Time) at the Le Parker Meridien Hotel in New York. Dynavax plans t...
Jul 27, 2010
BERKELEY, CA, Jul 27, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the promotion of J. Tyler Martin, M.D. to the newly-created position of President and the appointment of Dr. Martin to the company's Board of Directors. Dr. Martin joined Dynavax as Chief Medical Officer in February 200...
Jul 27, 2010
BERKELEY, CA, Jul 27, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported completing enrollment and the first immunizations of 39 subjects enrolled in its Phase 1 study of the company's Universal Flu vaccine. Safety and immunogenicity data from this study are anticipated in the fourth quarter ...
Jul 23, 2010
BERKELEY, CA, Jul 23, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) reported that equity awards were made to two new employees under the Company's 2010 Employment Inducement Award Plan ("the 2010 Plan"). The employees were granted options to purchase an aggregate of 13,000 shares of the Company's commo...
Jul 22, 2010
BERKELEY, CA, Jul 22, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the appointment of Daniel Kisner, M.D. to its Board of Directors. The addition of Dr. Kisner to the Dynavax Board brings its membership to 10. Dr. Kisner most recently served as a Partner at Aberdare Ventures and pr...
Jul 7, 2010
BERKELEY, CA, Jul 07, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the first human clinical trial in its Universal Flu vaccine program. The Phase 1 trial, which began vaccinating subjects in late June, will assess the safety and immunogenicity of N8295, the novel component of Dynavax's...
Jul 6, 2010
BERKELEY, CA, Jul 06, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the award of a $600,000 grant from the National Institutes of Health (NIH) to explore the feasibility of developing a universal vaccine to prevent infection by human papilloma virus (HPV). In contrast to the two approve...
Jun 16, 2010
BERKELEY, CA, Jun 16, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported in NATURE new data that may explain the resistance of lupus patients to glucocorticoid treatment. In the June 16, 2010 issue of NATURE, Dynavax scientists show that activation of cells of the innate immune system by two ...
May 27, 2010
BERKELEY, CA, May 27, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Data Safety Monitoring Board (DSMB) established for Dynavax's two ongoing Phase 3 trials for HEPLISAV(TM) has completed the second of its planned safety assessments. The evaluation included data from 2,264 subj...
May 6, 2010
BERKELEY, CA, May 06, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported completing the first immunizations of over 2,000 subjects enrolled in its large-scale Phase 3 study of HEPLISAV(TM). This starts a 12-month follow-up on these subjects and sets the study's completion for May 2011. Dynava...
May 6, 2010
BERKELEY, CA, May 06, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2010, including $30.1 million in cash and cash equivalents. Total cash for the first quarter 2010 does not include $41 million in net proceeds from the public offer...
Apr 27, 2010
BERKELEY, CA, Apr 27, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Data Safety Monitoring Board (DSMB) established for Dynavax's two ongoing Phase 3 trials for HEPLISAV(TM) has assessed subject safety data for 1,548 subjects that received their first injection and 1,225 subjec...
Apr 26, 2010
BERKELEY, CA, Apr 26, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today presented preclinical data that confirms the expected immunogenicity and mechanistic effects of its Universal Flu vaccine. In addition to the demonstrated ability of Dynavax's vaccine to generate cytotoxic T-cells and cytotoxic a...
Apr 14, 2010
BERKELEY, CA, Apr 14, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today presented Phase 2 clinical data that demonstrate HEPLISAV(TM)'s immunogenicity and rapid protection in patients with chronic kidney disease. In a poster session at the National Kidney Foundation Spring Clinical Meeting in Orlando...
Apr 13, 2010
BERKELEY, CA, Apr 13, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of an underwritten offering resulting in gross proceeds of $44 million, before deducting estimated offering expenses. 30,293,000 units are being sold at a per unit price of $1.4525. Each unit consists of one...
Apr 9, 2010
BERKELEY, CA, Apr 09, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) reported that equity awards were made to two new employees under the Company's 2010 Employment Inducement Award Plan ("the 2010 Plan"). The employees are focused on clinical and commercial development. Dynavax's Board of Directors adop...
Mar 23, 2010
BERKELEY, CA, Mar 23, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) will present for the first time a detailed analysis of safety data for HEPLISAV(TM), an investigational adult hepatitis B vaccine, including two major findings: -- The safety profile of HEPLISAV was comparable to that of En...
Mar 16, 2010
BERKELEY, CA, Mar 16, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today said that its large-scale Phase 3 study of HEPLISAV(TM) is fully enrolled, with immunization of subjects proceeding in accordance with the pre-specified safety monitoring plan. Dynavax indicated that it expects immunization of al...
Mar 15, 2010
BERKELEY, CA, Mar 15, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the successful completion of negotiations relating to Merck's reimbursement obligations under the former partnership agreements covering the clinical development and commercialization of HEPLISAV(TM), Dynavax's enhanced...
Feb 25, 2010
BERKELEY, CA, Feb 25, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it has selected a clinical vaccine candidate for its novel Universal Flu program, completed key preclinical studies, and is reviewing clinical plans with the FDA in anticipation of initiating a Phase I study by mid...
Feb 18, 2010
BERKELEY, CA, Feb 18, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the selection of a candidate for clinical development in its endosomal Toll-like Receptor (TLR) inhibitor collaboration with GlaxoSmithKline. The selected molecule DV1179, a bifunctional TLR inhibitor, has moved into ad...
Feb 16, 2010
BERKELEY, CA, Feb 16, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced that Health Canada, the Canadian equivalent of the U.S. Food and Drug Administration, has approved the initiation of the Company's next Phase 3 trials in Canada. Initiation of the Canadian studies is expected to facilitate en...
Feb 8, 2010
BERKELEY, CA, Feb 08, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today initiation of a large-scale Phase 3 trial designed to demonstrate the lot-to-lot consistency of commercial vaccine and to complete the safety database for HEPLISAV(TM), the Company's investigational adult hepatitis B va...
Jan 26, 2010
BERKELEY, CA, Jan 26, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today data from two studies that differentiate SD-101 from standard-of-care as well as emerging treatments for chronic HCV infection. The findings of a Phase 1b clinical trial and an in vitro study of SD-101's mechanism of ac...
Jan 12, 2010
BERKELEY, CA, Jan 12, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the addition of two new senior executives to direct key commercial and clinical activities prior to the launch of HEPLISAV(TM), an investigational adult hepatitis B vaccine. Brant Biehn, after more than 20 years wit...
Jan 4, 2010
BERKELEY, CA, Jan 04, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that stockholders approved the acquisition of Symphony Dynamo, Inc. (SDI), including approximately $20 million in cash and all rights to Dynavax's hepatitis C and cancer therapy programs. Dynavax expects the proceed...
Dec 9, 2009
BERKELEY, CA and DUSSELDORF, GERMANY, Dec 09, 2009 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that its GMP manufacturing facility in Duesseldorf, Germany has been approved for the commercial production of hepatitis B surface antigen, a key component of HEPLISAV(TM), the Company's investig...
Nov 19, 2009
BERKELEY, CA, Nov 19, 2009 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that enrollment has been completed for the first of three cohorts of patients receiving DV-601 hepatitis B therapy in a Phase 1b clinical trial. The safety profile of patients in the first cohort met pre-specified crite...
Nov 10, 2009
BERKELEY, CA, Nov 10, 2009 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it has exercised its option to purchase all of the equity of Symphony Dynamo, Inc. (SDI). As a result, Dynavax will acquire approximately $20 million in cash and regain all rights to its hepatitis C and cancer ther...
Nov 5, 2009
BERKELEY, Calif., Nov 05, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) announced today that Francis R. Cano, Ph.D. has been appointed to Dynavax's Board of Directors effective November 3, 2009. "A recognized scientific leader in vaccines and infectious diseases, Francis brings unique expertise and ...
Oct 29, 2009
BERKELEY, Calif., Oct 29, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced the first clinical data for HEPLISAVTM investigational hepatitis B vaccine in chronic kidney disease patients. These data will be presented in a poster session on Saturday, October 31, 2009 at the 47th An...
Oct 22, 2009
BERKELEY, Calif., Oct 22, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today reported financial results for the third quarter and nine months ended September 30, 2009. Dynavax reported $46.4 million in cash, cash equivalents, marketable securities and investments held by Symphony Dynamo, Inc. (SDI), ...
Oct 21, 2009
BERKELEY, Calif., Oct 21, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to report third quarter 2009 financial results after the market closes on Thursday, October 22, 2009. The Company also plans to host a webcast of a conference call on Thursday, October 22, 2009 at ...
Oct 20, 2009
BERKELEY, Calif., Oct 20, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that it plans to present at the Oppenheimer 20th Annual Healthcare Conference on Tuesday, November 3, 2009 at 10:15 am EST (7:15 am PST) at the Waldorf Astoria Hotel in New York. Dino Dina, M.D., President and Ch...
Sep 29, 2009
BERKELEY, Calif., Sep 29, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the initiation of a Phase 3 registration trial for HEPLISAVTM hepatitis B vaccine in individuals with chronic kidney disease. A second registration trial, a Phase 3 lot-to-lot consistency trial, is expected ...
Sep 22, 2009
BERKELEY, Calif., Sep 22, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today announced that an abstract with chronic kidney disease patient data for HEPLISAVTM, an investigational adult hepatitis B vaccine, will be presented at the 47th Annual Meeting of the Infectious Disease Society of America (ID...
Sep 10, 2009
BERKELEY, Calif., Sep 10, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the HEPLISAVTM Investigational New Drug (IND) application in individuals with chronic kidney disease. HEPLISAV is a Phase 3 ...
Aug 12, 2009
BERKELEY, Calif., Aug 12, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today announced that it has met with the European Medicines Evaluation Agency (EMEA) to discuss its plans for continued clinical development of HEPLISAVTM Phase 3 investigational adult hepatitis B vaccine in Europe. In a Scienti...
Aug 7, 2009
BERKELEY, Calif., Aug 07, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious diseases, today announced that Deborah A. Smeltzer, Vice President, Operations and Chief Financial Officer, i...
Aug 4, 2009
BERKELEY, Calif., Aug 04, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported financial results for the second quarter and six months ended June 30, 2009. Dynavax reported $53.0 million in cash, cash equivalents, marketable securities and investments held by Symphony Dynamo, Inc. (SDI), co...
Aug 4, 2009
BERKELEY, Calif., Aug 04, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today announced it has met with the U.S. Food and Drug Administration (FDA) to discuss its plans to resume development of HEPLISAVTM, the Company's Phase 3 investigational hepatitis B vaccine. Dynavax proposed the continued clin...
Jun 3, 2009
BERKELEY, Calif., Jun 03, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today presented additional Phase 3 clinical data for HEPLISAVTM hepatitis B vaccine in a poster session at the Digestive Disease Week (DDW) medical conference in Chicago. In addition to meeting its primary endpoint in thi...
May 18, 2009
BERKELEY, Calif., May 18, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX), a clinical-stage biopharmaceutical company, today announced six abstracts presenting data at the American Thoracic Society (ATS) medical conference in San Diego, California May 15 - 20, 2009. Under a worldwide collaboration, Dyn...
May 13, 2009
BERKELEY, Calif., May 13, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the award of a Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID). This grant will support the preclinical development of Dynavax's first-in-class ...
Apr 30, 2009
BERKELEY, Calif., Apr 30, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the presentation of preclinical data from its novel Universal Flu vaccine at two medical conferences this week. Through the addition of highly conserved antigens, Dynavax's Universal Flu vaccine is designed to off...
Apr 28, 2009
BERKELEY, Calif., Apr 28, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported financial results for the first quarter ended March 31, 2009. Over the coming year, Dynavax intends to advance the development of its diversified pipeline of products to meaningful value inflection points while s...
Apr 27, 2009
BERKELEY, Calif., Apr 27, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the oral presentation of additional Phase 3 clinical data for HEPLISAV(TM) hepatitis B vaccine in a session for late-breaking abstracts at the 44th Annual Meeting of the European Association for the Study of Liver...
Mar 11, 2009
BERKELEY, Calif., Mar 11, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today announced an extension of the term of its research collaboration with its pharmaceutical partner AstraZeneca until July 2010. Under this collaboration, the companies are developing novel therapies for the treatment ...
Mar 4, 2009
BERKELEY, Calif., Mar 04, 2009 (BUSINESS WIRE) -- Dynavax Technologies (Nasdaq:DVAX) today announced the appointment of J. Tyler Martin, M.D. as Chief Medical Officer. Dr. Martin will manage Dynavax's clinical affairs, including the development of Dynavax's three current clinical-stage product candidates and three preclinica...
Mar 2, 2009
BERKELEY, Calif., Mar 02, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2008 and provided a corporate update and financial outlook for 2009. "We are making progress in our discussions with the regulatory authorities...
Feb 27, 2009
Feb 27, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops a diversified pipeline of novel Toll-like Receptor (TLR) based product candidates. Based on Dynavax's proprietary technologies, these products specifically modify the innate immune res...
Feb 26, 2009
BERKELEY, Calif., Feb 26, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) announced today that it plans to report fourth quarter and year end 2008 financial results on Monday, March 2, 2009 before the market opens. About DynavaxDynavax Technologies Corporation, a clinical-stage biopharmaceutical compa...
Feb 9, 2009
BERKELEY, Calif., Feb 09, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced receipt of communication from the U.S. Food and Drug Administration (FDA) regarding the clinical hold on the two HEPLISAVTM Investigational New Drug (IND) Applications, for healthy adults and patients with ...
Dec 19, 2008
BERKELEY, Calif., Dec 19, 2008 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the termination of a global license and development collaboration agreement with Merck & Co., Inc. for HEPLISAVTM, a Phase 3 hepatitis B virus (HBV) vaccine. All rights to develop and commercialize HEPLISA...
Dec 17, 2008
LONDON & PHILADELPHIA & BERKELEY, Calif., Dec 17, 2008 (BUSINESS WIRE) -- GlaxoSmithKline (LSE:GSK) (NYSE:GSK) and Dynavax Technologies Corporation (NASDAQ:DVAX) today announced a worldwide strategic alliance to discover, develop and commercialize novel inhibitors of endosomal Toll-like Receptors (TLRs) for the treatment of ...
Dec 8, 2008
BERKELEY, Calif., Dec 08, 2008 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) announced today preclinical data showing results from a key component of the Company's novel Universal Flu vaccine candidate. Dynavax's Universal Flu vaccine is being developed to control influenza by providing protection that is...
Nov 25, 2008
BERKELEY, Calif., Nov 25, 2008 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX), a clinical-stage biotechnology company, announced today that Nasdaq has approved the Company's request to transfer the listing of its shares to The Nasdaq Capital Market from The Nasdaq Global Market effective November 26, 2008....
Nov 14, 2008
BERKELEY, Calif. - November 14, 2008 - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that on November 10, 2008, the Company received a notice from The Nasdaq Stock Market indicating that the Company is not in compliance with the continued listing requirements of The Nasdaq Global Market under Nasdaq Marketplace Rule 4450(a)(3),...
Nov 6, 2008
BERKELEY, Calif., Nov 06, 2008 (BUSINESS WIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that it will present at the Credit Suisse 2008 Healthcare Conference on Wednesday, November 12, 2008 at 3:00 p.m. MST (2:00 p.m. PST) in Phoenix, Arizona. Dino Dina, M.D., President and Chief Executive Officer, will present a corporate o...
Nov 3, 2008
BERKELEY, Calif., Nov 03, 2008 (BUSINESS WIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today reported financial results for the third quarter and nine months ended September 30, 2008. Dynavax's cash, cash equivalents, marketable securities and investments held by Symphony Dynamo, Inc. (SDI) totaled $64.3 million at September 30, 2008....
Oct 30, 2008
BERKELEY, Calif., Oct 30, 2008 (BUSINESS WIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that it plans to report third quarter 2008 financial results before the market opens on Monday, November 3, 2008. The company also plans to have a corporate overview presentation at the Oppenheimer 19th Annual Healthcare Conference i...
Oct 21, 2008
BERKELEY, Calif. & WHITEHOUSE STATION, N.J., Oct 21, 2008 (BUSINESS WIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) and Merck & Co., Inc. have received communication from the U.S. Food and Drug Administration (FDA) regarding the two companies' response to the agency's request for safety information relating to the clinical hold on the two I...
Sep 29, 2008
BERKELEY, Calif., Sep 29, 2008 (BUSINESS WIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced it has been awarded a $17 million contract to develop its advanced immunostimulatory sequences (ISS) technology using Toll-Like Receptor 9 (TLR9) agonists as vaccine adjuvants. This five-year contract was awarded by the National Inst...
Sep 22, 2008
BERKELEY, Calif., Sep 22, 2008 (BUSINESS WIRE) -- Dynavax Technologies, Inc. (NASDAQ:DVAX) today announced receipt of a $4.5 million milestone payment from its partner AstraZeneca AB for the nomination of candidate drug AZD1419 for the treatment of asthma and chronic obstructive pulmonary disease (COPD). As part of this potential $136 million devel...
Aug 5, 2008
BERKELEY, Calif., Aug 05, 2008 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today reported financial results for the second quarter and six months ended June 30, 2008. As of June 30, 2008, Dynavax reported cash, cash equivalents, marketable securities and investments held by Symphony Dynamo, Inc. (SDI) totaling $63.1 millio...
Aug 5, 2008
BERKELEY, Calif. & WHITEHOUSE STATION, N.J., Aug 05, 2008 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) and Merck & Co., Inc. announced today top-line immunogenicity results from a Phase 3 clinical trial comparing HEPLISAV(TM), an investigational hepatitis B virus (HBV) vaccine, to a currently marketed HBV vaccine, Engerix-B...
Jul 23, 2008
BERKELEY, Calif., Jul 23, 2008 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today announced an agreement with Novartis Vaccines and Diagnostics, Inc. for the supply and development, and possible commercialization, of Dynavax's novel Universal Influenza Vaccine in collaboration with Novartis. Under the agreement Novartis will pr...
May 16, 2008
BERKELEY, Calif., May 16, 2008 (BUSINESS WIRE) -- Dynavax Technologies (Nasdaq:DVAX) will webcast this morning a discussion of the TOLAMBA Chamber study data and provide an updated financial outlook for 2008. A live webcast will begin at 8:45 a.m. EDT (5:45 a.m. PDT). The webcast can be accessed from Dynavax's website at www.dynavax.com under t...
May 16, 2008
BERKELEY, Calif., May 16, 2008 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today reported primary endpoint data from a chamber study of TOLAMBA(TM) that showed a measurable clinical benefit, reducing total nasal symptom score (TNSS) by 41% vs. placebo in 253 patients in the intent-to-treat population (p=0.09) and by 51% vs. pl...
Apr 29, 2008
BERKELEY, Calif., Apr 29, 2008 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported financial results for the first quarter ended March 31, 2008. As of March 31, 2008, Dynavax reported cash, cash equivalents, marketable securities and investments held by Symphony Dynamo, Inc. (SDI) totaling $73.2 million. This compa...
Apr 17, 2008
BERKELEY, Calif. & WHITEHOUSE STATION, N.J., Apr 17, 2008 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) and Merck & Co, Inc. announced today the receipt of formal written notification from the US Food and Drug Administration (FDA) detailing a request for information relating to the previously announced clinical hold placed on th...
Mar 17, 2008
BERKELEY, Calif. & WHITEHOUSE STATION, N.J., Mar 17, 2008 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) and Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the two Investigational New Drug (IND) applications for HEPLISAV(TM), an investigational hepatitis B vaccine ...
Feb 28, 2008
BERKELEY, Calif., Feb 28, 2008 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) announced today Michael S. Ostrach, Vice President and Chief Business Officer, will present an overview of the company at the Susquehanna Financial Group's Second Annual SIGnificant Options in Healthcare Conference on Wednesday, March 5, 2008 at 1:00 p....
Feb 25, 2008
BERKELEY, Calif., Feb 25, 2008 (BUSINESS WIRE) -- Dynavax Technologies (Nasdaq:DVAX) today announced that Dr. Martin E. Sanders has been appointed Executive Vice President and Chief Development Officer. Sanders will direct Dynavax's product development programs, including pre-clinical, process development, clinical, and regulatory activities. D...
Feb 19, 2008
BERKELEY, Calif., Feb 19, 2008 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) today reported financial results for the fourth quarter and year ended December 31, 2007. As of December 31, 2007, Dynavax reported cash, cash equivalents, marketable securities and investments held by Symphony Dynamo, Inc. (SDI) totaling $88.2 mill...
Feb 15, 2008
BERKELEY, Calif., Feb 15, 2008 (BUSINESS WIRE) -- Dynavax Technologies (Nasdaq:DVAX) will report fourth quarter and year-end 2007 financial results and provide guidance for 2008 on Tuesday, February 19, 2008. A live webcast will begin at 4:15 p.m. EST (1:15 p.m. PST). The webcast can be accessed from Dynavax's website at www.dynavax.com under t...
Nov 26, 2007
BERKELEY, Calif., Nov 26, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- In a paper appearing online in the December issue of The European Journal of Immunology (Vol. 37, Issue 12), Dynavax scientists report the results of studies made possible under a grant from the Alliance for Lupus Research (ALR). In the article entitled, "Treatment of ...
Nov 12, 2007
BERKELEY, CA, Nov. 12, 2007 -- Dynavax Technologies Corporation (Nasdaq: DVAX) presented yesterday a detailed analysis of data from the company's large-scale DARTT (SAR09) trial evaluating TOLAMBATM, a novel therapy for ragweed allergic rhinitis. The data were reported yesterday at the annual meeting of the American College of Allergy, Asthma an...
Nov 9, 2007
BERKELEY, Calif., Nov 09, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today Dino Dina, President and CEO, will present an overview of the company at the Credit Suisse 2007 Healthcare Conference in Phoenix, Arizona on Tuesday, November 13th at 4:00 p.m. MST (6:00 p.m. EST). The pre...
Nov 1, 2007
BERKELEY, Calif., Nov 01, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today Michael S. Ostrach, Vice President and Chief Business Officer, will present an overview of the company at two investor conferences in New York City the first week of November. Ostrach will present at the C...
Nov 1, 2007
BERKELEY, Calif., and WHITEHOUSE STATION, N.J., Nov 01, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) and Merck & Co., Inc. (NYSE: MRK) today announced a global license and development collaboration agreement to jointly develop HEPLISAV(TM), a novel investigational hepatitis B vaccine, which ...
Nov 1, 2007
BERKELEY, Calif., Nov 01, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported financial results for the third quarter and nine months ended September 30, 2007. The results do not include the financial impact of today's arrangement with Merck. As of September 30, 2007, Dynavax rep...
Oct 22, 2007
BERKELEY, Calif., Oct 22, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it had begun dosing of TOLAMBA(TM), its novel ragweed allergy therapy, to subjects as part of an environmental exposure chamber study that is expected to enroll a total of 300 subjects. Subjects are be...
Sep 19, 2007
BERKELEY, Calif., Sept 19, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today that the seroprotection of HEPLISAV at 50 weeks after the first vaccination remained at 100% while the seroprotection of the comparator, GlaxoSmithKline's Engerix-B(R); vaccine declined. The data show...
Sep 18, 2007
BERKELEY, Calif., Sept 18, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today Deborah Smeltzer, Vice President and Chief Financial Officer, will present an overview of the company at the UBS 2007 Global Life Sciences Conference in New York, New York on Tuesday, September 25th at 9:...
Sep 6, 2007
BERKELEY, Calif., Sept 06, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today Dr. Dino Dina, President and Chief Executive Officer, will present an overview of the company at the Bear Stearns 20th Annual Healthcare Conference in New York, New York on Monday, September 10th at 9:00 ...
Aug 16, 2007
BERKELEY, Calif. - August 16, 2007 - Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that the U.S. Patent Office has issued the company a broad composition of matter patent covering the company's proprietary second-generation TLR9 agonists. The claims cover a broad class of novel TLR9 agonists containing short DNA seque...
Aug 7, 2007
BERKELEY, Calif., Aug 07, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today that the National Institutes of Allergy and Infectious Disease (NIAID), a division of the National Institutes of Health (NIH), has awarded a two-year $3.25 million grant to continue development of a novel ...
Jul 31, 2007
BERKELEY, Calif., July 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported financial results for the second quarter and six months ended June 30, 2007. As of June 30, 2007, Dynavax reported cash, cash equivalents, marketable securities and investments held by Symphony Dynamo,...
Jul 18, 2007
BERKELEY, Calif., July 18, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that Deerfield Management, a healthcare investment fund, has committed up to $30 million in project financing to accelerate the development of Dynavax's allergy franchise. The funding will: (1) finance the...
Jul 12, 2007
BERKELEY, Calif., July 12, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today the completion of enrollment of its Phase 3 pivotal clinical trial of HEPLISAV(TM), its novel hepatitis B virus (HBV) vaccine. Dynavax's U.S. safety and immunogenicity study - a second key clinical trial ...
Jun 28, 2007
WELLESLEY, Mass. and BERKELEY, Calif., June 28, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Coley Pharmaceutical Group, Inc. (Nasdaq: COLY) and Dynavax Technologies Corporation (Nasdaq: DVAX) today announced they have entered into a license agreement relating to certain TLR Therapeutics(TM) patents from Coley. Under the terms of the ...
Jun 26, 2007
BERKELEY, Calif., June 26, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today the initiation of three clinical trials to support licensure of HEPLISAV(TM), its novel hepatitis B virus (HBV) vaccine: -- The ongoing multi-center pivotal Phase 3 trial in Canada has been ...
Jun 11, 2007
BERKELEY, Calif., June 11, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today Deborah Smeltzer, Chief Financial Officer, will present an overview of the company at the Sixth Annual Needham Biotechnology and Medical Technology Conference in New York, New York on Thursday, June 14 at...
Jun 4, 2007
BERKELEY, Calif., June 4, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today Dr. Dino Dina, President and Chief Executive Officer, will present an overview of the company at the Third Annual Bear Stearns Biotech Confab in Boston, Massachusetts on Thursday, June 7 at 9:10 a.m. Easte...
May 29, 2007
BERKELEY, Calif., May 29, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today Michael Ostrach, Chief Business Officer, will present an overview of the company at the Bank of America 2007 Health Care Conference in Las Vegas, Nevada. Mr. Ostrach is scheduled to present on Friday, June...
May 2, 2007
BERKELEY, Calif., May 2, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported financial results for the first quarter ended March 31, 2007. As of March 31, 2007, Dynavax reported cash, cash equivalents, marketable securities and investments held by Symphony Dynamo, Inc. (SDI) tota...
Apr 6, 2007
BERKELEY, Calif., April 6, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today Michael Ostrach, Chief Business Officer, will present an overview of the company at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference in New York City. Mr. Ostrach is sche...
Mar 13, 2007
BERKELEY, Calif., March 13, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today Michael Ostrach, Chief Business Officer, will present an overview of the company at Cowen and Company's 27th Annual Health Care Conference at the Boston Marriott Copley Place in Boston. Mr. Ostrach is sc...
Mar 1, 2007
BERKELEY, Calif., March 1, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that it had initiated a Phase 1 trial of its novel therapy for chronic hepatitis B virus (HBV) infection. The trial is being conducted in Hamburg, Germany and will enroll 20 healthy subjects to evaluate t...
Feb 23, 2007
BERKELEY, Calif., Feb 23, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported interim data from the first year of its two-year ragweed allergy trial known as DARTT, including a prespecified regional analysis of sites that clearly showed a therapeutic benefit of TOLAMBA in the Midwest...
Feb 23, 2007
BERKELEY, Calif., Feb 23, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today provided its financial outlook for 2007. The following statements are forward-looking and are based on current expectations. Actual results may differ materially. Except as expressly set forth below, these state...
Feb 22, 2007
BERKELEY, Calif., Feb 22, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today that it will host a webcast on Friday, February 23, 2007 at 7:00 a.m. PT (10 a.m. ET) to report data that will be presented at the AAAAI meeting in San Diego this weekend and to provide the Company's 2007 ...
Feb 13, 2007
BERKELEY, Calif., Feb. 13 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2006. As of December 31, 2006, Dynavax reported cash, cash equivalents, marketable securities and investments held by Symphony Dynamo, Inc. (SDI...
Jan 8, 2007
Insufficient Ragweed Allergic Disease in Placebo and Treated Groups Prevent Measurement of Therapeutic Effect BERKELEY, Calif., Jan. 8 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today that the analysis of interim one-year data from its two-year DARTT ragweed allergy trial ind...
Dec 20, 2006
Canadian Site First to Dose in Multi-National Trial BERKELEY, Calif., Dec. 20 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today the initiation of a pivotal Phase 3 clinical trial of HEPLISAV, its hepatitis B virus (HBV) vaccine in Canada. Sites in the United States and in Europe are schedul...
Dec 12, 2006
Board Member Jan Leschly of Care Capital Resigns BERKELEY, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that Dr. David M. Lawrence, Retired Chairman and Chief Executive Officer of Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals (KFHP/KFH), has joined Dyna...
Dec 10, 2006
Combination of TLR9 Agonist and Rituximab Shows Biological Activity, Potential for Improved Progression-Free Survival BERKELEY, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today preliminary data from an ongoing open label Phase 2a study of the company'
Dec 5, 2006
Combination of TLR9 Agonist and Chemotherapy Regimen Studied BERKELEY, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today the initiation of a Phase 1 dose escalation clinical trial of its TLR9 agonist in combination with a standard chemotherapeutic regimen for metasta...
Dec 4, 2006
Equivalent Seroprotection from Shorter Two-Dose Vaccination Schedule BERKELEY, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today positive results from a Phase 2 trial comparing two different vaccination schedules of HEPLISAV, its hepatitis B virus (HBV) vaccine. The prim...
Nov 28, 2006
In Difficult-to-Immunize Population, Shows Clear Superiority to Conventional Vaccine BERKELEY, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today statistically significant results from the primary endpoint analysis of a Phase 3 tr
Nov 12, 2006
New Analysis Confirms TOLAMBA Benefits Entire Ragweed Allergy Patient Population; Confirms Mechanism of Action BERKELEY, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported additional data from a Phase 2b study showing TOLAMBA™, the company's novel ragw...
Oct 31, 2006
BERKELEY, Calif., Oct 31, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that Michael Ostrach has joined the company as vice president, chief business officer and general counsel. Ostrach will direct Dynavax's corporate development and legal activities. Ostrach ...
Oct 26, 2006
BERKELEY, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported financial results for the third quarter and nine-months ended September 30, 2006. As of September 30, 2006, Dynavax reported cash, cash equivalents, marketable securities and investments held by Symphony Dy...
Oct 20, 2006
BERKELEY, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) will announce its third quarter 2006 financial results on Thursday, October 26, 2006. The announcement will be followed by a live webcast at 1:30 p.m. PT / 4:30 p.m. ET of a discussion by Dynavax Technologies management of third quar...
Oct 19, 2006
Preclinical Studies Show TLR9 Agonists Conjugated to Conserved Viral Proteins Provide 30-Fold Dose-Sparing of Standard Vaccine Components BERKELEY, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that tomorrow, Friday, October 20, at the Second Intern...
Oct 10, 2006
BERKELEY, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced the closing of its underwritten public offering of 7,130,000 shares of its common stock that included the exercise of the underwriter's over-allotment option of 930,000 shares, at a price of $4.40 per share. The offering wa...
Oct 4, 2006
BERKELEY, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today the pricing of a common stock offering of 6,200,000 shares of its common stock at $4.40 per share for approximately $27 million in gross proceeds, before commissions and expenses. All shares of the common stock offered by Dy...
Oct 4, 2006
BERKELEY, Calif., Oct. 4 /PRNewswire-FirstCall/ -- The NEW ENGLAND JOURNAL OF MEDICINE (Vol. 355, October 5, 2006, No.14), today reported that a new approach to allergy therapy not only reduced the acute allergic responses of individuals with ragweed allergies but also sustained that effect for over 12 months. The novel treatment, called...
Sep 21, 2006
BERKELEY, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that Deborah Smeltzer, Vice President, Operations and CFO, will present an overview of the company at the UBS Global Life Sciences conference, September 26, 2006 at 4:00 p.m. Eastern, in New York City. The webcast present...
Sep 6, 2006
BERKELEY, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) has entered into a research collaboration and license agreement with AstraZeneca for the discovery and development of TLR-9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The c...
Aug 31, 2006
BERKELEY, Calif., Aug. 31 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that the company has secured an equity financing commitment of up to $30 million from Azimuth Opportunity Ltd. Acqua Capital Management is an advisor to Azimuth Opportunity. During the 18-month term of the equity financi...
Aug 21, 2006
Conjugation of TLR9 Agonists to Conserved Viral Proteins Shows Protection Against 'Antigenic Shift,' the Precursor of a Flu Pandemic BERKELEY, Calif., Aug. 21 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today presented new preclinical data showing that its influenza (flu) vaccine confers imm...
Aug 16, 2006
Former Chairman Dan Janney Retires From Board of Directors BERKELEY, Calif., Aug. 16 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced the appointment of Peggy V. Phillips to Dynavax's Board of Directors as a Class III director to serve until the annual meeting of stockholde...
Jul 27, 2006
BERKELEY, Calif., July 27 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported financial results for the second quarter 2006. During the second quarter 2006, Dynavax completed two significant transactions designed to expand the Company's operations and advance its early-stage pipeline. These t...
Jul 13, 2006
BERKELEY, Calif., July 13, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies (Nasdaq: DVAX) will announce its second quarter 2006 financial results on Thursday, July 27, 2006. The announcement will be followed by a live webcast at 5:00 p.m. ET of a discussion by Dynavax Technologies management of second qua...
Jun 7, 2006
Physician and Patient Demand Led to Accelerated Recruitment of More Than 700 Subjects BERKELEY, Calif., June 7 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that enrollment in the Dynavax Allergic Rhinitis TOLAMBA Trial (DARTT) has exceeded expectatio...
Jun 5, 2006
BERKELEY, Calif., June 5 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that Dino Dina, MD, President and CEO, will present an overview of the company at the Pacific Growth Equities Life Sciences Growth conference, June 13, 2006 at 1:00 p.m. Pacific, in San Francisco. The webcast presentation ma...
May 24, 2006
BERKELEY, Calif., May 24 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that Dino Dina, MD, President and CEO, will present an overview of the company at the Friedman Billings Ramsey Growth Investor conference, May 31, 2006 at 12:45 p.m. Eastern, in New York. The webcast presentation may be accessed b...
May 4, 2006
Award Based on 1994 Patent Granted to Rhein Biotech GmbH Founder for Hansenula Yeast-Based Protein Production System for Hepatitis B Vaccine BERKELEY, Calif., May 4 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that Dr. Zbigniew Janowicz, managing director and co-founder of Rhein Biotech GmbH, ...
Apr 27, 2006
BERKELEY, Calif., April 27 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported financial results for the first quarter 2006. Total revenues for the first quarter ended March 31, 2006 were $0.3 million compared to $12.7 million for the same period in 2005. Revenues in the first quarter 2006...
Apr 26, 2006
BERKELEY, Calif., April 26, 2006 /PRNewswire via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that Robert L. Coffman, Ph.D., vice president and chief scientific officer, has been elected to the National Academy of Sciences (NAS). The election was held on April 25th during the business session of the 143rd...
Apr 25, 2006
BERKELEY, Calif., April 25 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that Dino Dina, MD, President and CEO, will present an overview of the company at the Deutsche Bank Securities 31st Annual Healthcare conference, May 3, 2006 at 2:30 p.m. Eastern, in Boston. The webcast presentation may be acce...
Apr 24, 2006
BERKELEY, Calif., April 24 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that it has completed the acquisition of biopharmaceutical and vaccine manufacturer Rhein Biotech GmbH for a cash transaction of approximately $12.4 million based on current exchange rates. In addition to the purchase price, Dyn...
Apr 20, 2006
BERKELEY, Calif., April 20 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) will announce its first quarter 2006 financial results on Thursday, April 27, 2006. The announcement will be followed by a live webcast at 5:00 p.m. ET of a discussion by Dynavax Technologies management of first quarter 2006 financial res...
Apr 19, 2006
Collaborative Financing From Symphony Capital Partners, LP Designed to Advance Next-Generation TLR-Agonist Pipeline BERKELEY, Calif., April 19 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced an agreement with Symphony Capital Partners, LP and its co-investors to provide $50 ...
Mar 30, 2006
BERKELEY, Calif., March 30, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that Dino Dina, MD, President and CEO, will present an overview of the company at the CIBC World Markets Annual Biotechnology & Specialty conference, April 4, 2006 at 9:30 a.m. Eastern, in New York. The...
Mar 27, 2006
Dynavax Gains Ownership of GMP Vaccine Manufacturing Facility, Vaccine Pipeline and HEPLISAV Commercialization RightsBERKELEY, Calif., March 27, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced its plan to acquire biopharmaceutical and vaccine manufacturer Rhein Biotech Gmb...
Mar 20, 2006
BERKELEY, Calif., March 20 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that Dino Dina, MD, President and CEO, will present an overview of the company at the Bear Stearns Biotech West Coast Confab at the Fairmont Hotel in San Francisco. Dr. Dina's presentation will be webcast live at 11:0...
Mar 15, 2006
BERKELEY, Calif., March 15, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported financial results for the fourth quarter and year-end 2005. Total revenues for the fourth quarter ended December 31, 2005 were $0.6 million compared to $2.5 million for the same period in ...
Mar 6, 2006
Safety and Efficacy Endpoints Achieved Following Single, Short Course of TherapyBERKELEY, Calif., March 6, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) presented positive results from a well-controlled, two-year, multi-center Phase 2/3 clinical trial of TOLAMBA™, a ragweed aller...
Mar 2, 2006
BERKELEY, Calif., March 2 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) will announce its fourth quarter and full-year 2005 financial results on Wednesday March 15, 2006. The announcement will be followed by a live webcast at 5:00 p.m. ET of a discussion by Dynavax Technologies management of fourth quarter 2005...
Mar 1, 2006
BERKELEY, Calif., March 1 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today provided an update on key aspects of the development program for TOLAMBA™, a ragweed immunotherapeutic. AAAAI Preview Dynavax plans to report the positive safety and efficacy data from the company's Phase 2/3 c...
Feb 23, 2006
BERKELEY, Calif., Feb. 23 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that Arnold L. Oronsky, PhD, has been elected chairman of Dynavax's Board of Directors. Dr. Oronsky is a general partner with InterWest Partners, and has served on Dynavax's Board of Directors since 1996. Daniel Janney, who has s...
Feb 15, 2006
BERKELEY, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that safety and efficacy data from the company's Phase 2/3 clinical trial of TOLAMBA™, its ISS-based ragweed allergy immunotherapeutic, will be presented in an oral abstract session at the Annual Meeting of the American Associati...
Feb 8, 2006
BERKELEY, Calif., Feb. 8 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that Dino Dina, MD, President and CEO, will present at two focus sessions at the BIO CEO & Investor Conference 2006 at the Waldorf-Astoria Hotel in New York City. Both focus sessions are scheduled for Wednesday, February 15th....
Jan 24, 2006
BERKELEY, Calif., Jan. 24 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that Pacific Growth Equities, LLC will host an informal conversation with Dr. Dino Dina, President and CEO, and Dr. Dan Levitt, Chief Medical Officer, of Dynavax to further discuss the Phase 2/3 TOLAMBA™ data announced on January...
Jan 18, 2006
Statistical Significance Achieved in Primary Endpoint (p=0.024) and Major Secondary Endpoints; Pivotal Phase 3 Trial Anticipated to Begin First Half of 2006 BERKELEY, Calif., Jan. 18 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that results from a tw...
Dec 19, 2005
Primary Endpoint Results Showing Superior Seroprotection, Robustness and Durability of Protective Effect Over GSK's Engerix-B® in Older Adult Population Presented at ICAACBERKELEY, Calif., Dec 19, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced positive results from...
Dec 7, 2005
BERKELEY, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that safety and efficacy data from the company's Phase 2/3 clinical trial of HEPLISAV, its ISS-based hepatitis B vaccine, compared to GlaxoSmithKline's Engerix-B® vaccine in an older adult population will be presented in a...
Nov 10, 2005
BERKELEY, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that the underwriters of its previously announced follow-on offering have purchased an additional 720,000 shares of common stock from Dynavax pursuant to the option granted to the underwriters to cover over-allotments. The...
Nov 7, 2005
Presentation at ACAAI Confirms Same High Dose Level Can Be Used in Both Adults and Children BERKELEY, Calif., Nov. 7 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced presentation of data from a Phase 1 trial of its ragweed allergy immunotherapy, TOLAMBA, demonstra...
Nov 2, 2005
BERKELEY, Calif., Nov 02, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that Nancy L. Buc has joined the Company's Board of Directors. Ms. Buc is a partner in the Washington, DC law firm Buc & Beardsley, and has had a long and distinguished legal career with a strong focus on...
Nov 1, 2005
BERKELEY, Calif., Nov. 1 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced the initiation of a Phase 1 clinical trial of HEPLISAV, its ISS-based hepatitis B (HBV) vaccine in patients with end-stage renal failure (pre-dialysis). The trial will be conducted at multiple centers in the United States and will...
Oct 27, 2005
BERKELEY, Calif., Oct 27, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported financial results for the third quarter 2005. Total revenues for the quarter ended September 30, 2005 were $0.4 million compared to $3.7 million for the same period in 2004. Revenues in the ...
Oct 25, 2005
BERKELEY, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announced today that Dino Dina, MD, President, CEO and Director, will present an overview of the company at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference at the New York Palace Hotel, and at the CIBC World Markets 16th Annual Healthca...
Oct 19, 2005
BERKELEY, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) will announce its 2005 third quarter financial results on Thursday October 27, 2005. The announcement will be followed by a live webcast at 5:00 p.m. ET of a discussion by Dynavax Technologies management of third quarter 2005 financial res...
Oct 14, 2005
BERKELEY, Calif., Oct. 14 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced the closing of its underwritten public offering of 5,000,000 shares of its common stock at a price of $6.25 per share. The offering was made under the company's existing shelf registration statement and resulted in net pro...
Oct 11, 2005
BERKELEY, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today the pricing of 5,000,000 shares of its common stock at $6.25 per share pursuant to an effective shelf registration statement. This represents an increase of 1,000,000 shares over the company's previously announced intentio...
Oct 3, 2005
BERKELEY, Calif., Oct. 3 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today that it intends to offer 4,000,000 shares of its common stock in a public offering pursuant to an effective shelf registration statement. Dynavax intends to grant the underwriters in the offering an option to purchase up to...
Sep 27, 2005
BERKELEY, Calif., Sept 27, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced the selection of TOLAMBA™ and HEPLISAV™ as brand names for its ragweed allergy immunotherapy (formerly, AIC) and hepatitis B prophylaxis products, respectively. Both TOLAMBA and HEPLISAV are in Phase 3 t...
Aug 31, 2005
BERKELEY, Calif., Aug 31, 2005 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) announced today that Dino Dina, MD, President, CEO and Director, will present an overview of the company at the Bear Stearns 18th Annual Healthcare Conference at the Grand Hyatt New York in New York City. Dr. Dina's presentation w...
Aug 29, 2005
BERKELEY, Calif., Aug 29, 2005 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that it has filed a shelf registration statement with the Securities and Exchange Commission (SEC) to sell from time to time up to $75 million, in aggregate, of its common stock. After the registration statement has b...
Aug 17, 2005
BERKELEY, Calif., Aug. 17 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that Stanley A. Plotkin, MD, the distinguished virologist and vaccine developer, has joined the Company's Board of Directors. Dr. Plotkin developed the rubella vaccine now in standard use, and has worked extensively on the develo...
Jul 28, 2005
BERKELEY, Calif., July 28 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported financial results for the second quarter 2005. Total revenues for the quarter ended June 30, 2005 were $1.0 million compared to $5.5 million for the same period in 2004. Revenues in the second quarter 2005 reflec...
Jul 28, 2005
BERKELEY, Calif., July 14, 2005 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), will hold its quarterly conference call to discuss second quarter results on Thursday, July 28, 2005 at 5:00 p.m. ET. This call is being webcast by Thomson/CCBN and can be accessed at Dynavax's web site at www.Dynava...
Jul 14, 2005
BERKELEY, Calif., July 14 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) will announce its second quarter 2005 financial results on Thursday, July 28, 2005 at 4:00 p.m. ET. The announcement will be followed by a live webcast at 5:00 p.m. ET of a discussion by Dynavax Technologies management of second quarter 200...
Jul 14, 2005
BERKELEY, Calif., July 14, 2005 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), will hold its quarterly conference call to discuss second quarter results on Thursday, July 28, 2005 at 5:00 p.m. ET. This call is being webcast by Thomson/CCBN and can be accessed at Dynavax's web site at www.Dynava...
Jul 11, 2005
Study Designed to Support Pivotal AIC Phase 3 TrialBERKELEY, Calif., July 11, 2005 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) announced that enrollment in the company's clinical trial of its AIC (Amb a 1 immunostimulatory conjugate) ragweed allergy immunotherapy in ragweed allergic children has exceeded ex...
Jun 23, 2005
BERKELEY, Calif., June 23 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced the initiation of a pivotal Phase 3 clinical trial of its hepatitis B (HBV) vaccine. The pivotal Phase 3 trial is designed to compare the effectiveness of Dynavax's HBV vaccine to GlaxoSmithKline's Engerix-B® HBV vaccine ...
Jun 14, 2005
Statistically Significant Protective Response Achieved in Difficult to Immunize Population; Results to Be Presented at Upcoming Medical Meeting BERKELEY, Calif., June 14 /PRNewswire-FirstCall/ Dynavax Technologies (Nasdaq: DVAX) announced positive data from the primary endpoint analysis of the company's hepatitis B v...
May 25, 2005
BERKELEY, Calif., May 25, 2005 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) announced today that Dino Dina, MD, President, CEO and Director, will present an overview of the company at the Pacific Growth Equities 2005 Life Sciences Growth Conference at the Mark Hopkins InterContinental hotel in San Francisco. ...
May 23, 2005
BERKELEY, Calif., May 23 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announced today that Dino Dina, M.D., President, CEO and Director, will present an overview of the company at the Friedman Billings Ramsey 9th Annual Growth Conference at the Millennium Broadway Hotel in New York City. Dr. Dina's presentati...
May 9, 2005
Data Generated Under NIAID Grant to Develop Pandemic Flu VaccineBERKELEY, Calif., May 9, 2005 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) presented data today from preclinical studies showing that the company's immunostimulatory sequence (ISS) based influenza (flu) vaccine induces an immune response potenti...
Apr 28, 2005
BERKELEY, Calif., April 28, 2005 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported financial results for the first quarter 2005. Revenue for the first quarter ended March 31, 2005 was $12.7 million compared to $3.2 million for the same period in 2004. In March 2005, Dynavax and UCB ...
Apr 21, 2005
BERKELEY, Calif., April 21 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announced today that Dino Dina, MD, President , CEO and Director, will present an overview of the company at the Deutsche Bank 30th Annual Health Care Conference at the Hyatt Regency Hotel in Baltimore, Maryland. Dr. Dina's presentation w...
Apr 20, 2005
BERKELEY, Calif., April 20, 2005 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) will announce its first quarter 2005 financial results on Thursday, April 28, 2005 at 4:00 p.m. ET. The announcement will be followed by a live webcast at 5:00 p.m. ET of a discussion by Dynavax Technologies management of first ...
Apr 20, 2005
BERKELEY, Calif., April 20 /PRNewswire/ -- Dynavax Technologies (Nasdaq: DVAX), working in vaccines for ragweed allergy and hepatitis B, will hold its quarterly conference call to discuss 2005 first quarter results on Thursday, April 28, 2005, at 5:00 p.m. Eastern Time. This call is being webcast by Thomson/CCBN and can be acc...
Mar 29, 2005
BERKELEY, Calif., March 29 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announced today that Dino Dina, MD, President and CEO, will present an overview of the company at the Thomson Financial/BioCentury Future Leaders in the Biotech Industry conference at the Millennium Broadway hotel in New York City. Dr. Di...
Mar 21, 2005
BERKELEY, Calif., March 21 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announced that data from a Phase 1 clinical trial of the company's AIC ragweed allergy immunotherapy showed that AIC treatment resulted in a clinically significant improvement in symptoms (p=0.052) and a parallel reduction in medication usage during ...
Mar 21, 2005
BERKELEY, Calif., March 21, 2005 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) presented data from preclinical models suggesting that the company's immunostimulatory sequence (ISS) based anthrax vaccine has the potential to confer higher levels of immunity quickly and effectively against the threat of anthrax infec...
Mar 18, 2005
Companies Reach Amicable Agreement to End CollaborationBERKELEY, Calif., March 18, 2005 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) announced that the Company and UCB Farchim, SA (UCB) have agreed to end their development and commercialization collaboration in seasonal allergy products. UCB will return all ...
Feb 17, 2005
BERKELEY, Calif., Feb 17, 2005 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) announced today that Dino Dina, MD, President and CEO, will discuss the Company's approaches to treat allergy and asthma during a focus session, entitled "Breathtaking New Respiratory Drugs for COPD, Asthma and Allergies," at the BIO CEO &...
Feb 15, 2005
BERKELEY, Calif., Feb 15, 2005 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported financial results for the fourth quarter and year-end 2004. The Company's financial results reflect an increase in clinical development activity as Phase 2/3 programs in ragweed allergy immunotherapy and in hepat...
Feb 8, 2005
BERKELEY, Calif., Feb. 8 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) will announce its 2004 fourth quarter and year-end financial results on Tuesday February 15, 2005. The announcement will be followed by a live webcast at 5:00 p.m. ET of a discussion by Dynavax Technologies management of fourth quarter and y...
Feb 7, 2005
BERKELEY, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) will announce it's 2004 fourth quarter and year-end financial results on Tuesday February 15, 2005. The announcement will be followed by a live webcast at 5:00 p.m. EST of a discussion by Dynavax Technologies management of fourth quarter and...
Jan 18, 2005
BERKELEY, Calif., Jan. 18 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announced today that Dino Dina, MD, President and CEO, will present an overview of the company at the Piper Jaffray Health Care Conference in New York City. Dr. Dina's presentation will be webcast live at 3:30 p.m. ET on Tuesday, January 2...
Jan 10, 2005
BERKELEY, Calif., Jan 10, 2005 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) has pioneered a new approach to treating autoimmune disease based upon a novel class of oligonucleotides, named immunoregulatory sequences (IRS), that specifically inhibit the toll-like receptor (TLR)-induced inflammatory response implicat...
Jan 5, 2005
BERKELEY, Calif., Jan. 5 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announces that Deborah A. Smeltzer has been appointed Vice President, Operations and Chief Financial Officer. Ms. Smeltzer brings to Dynavax more than 20 years of operating, business and financial management experience. Ms. Smeltzer joins D...
Dec 20, 2004
Positive Trends Relative to Primary and Secondary Endpoints Demonstrated BERKELEY, Calif., Dec. 20 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announced that the one-year interim analysis of the company's two-year Phase 2/3 clinical trial of its ragweed allergy ISS-based therapeutic (AIC, or Amb a 1 ISS conjug...
Dec 9, 2004
Highly Statistically Significant Protective Response (p=0.0001) Achieved in Difficult to Immunize Population After Two DosesBERKELEY, Calif., Dec 9, 2004 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) announced that data from an interim analysis of the company's hepatitis B virus (HBV) vaccine Phase 2/3 clinica...
Nov 15, 2004
BERKELEY, Calif., Nov 15, 2004 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) presented data from preclinical models showing that the company's immunostimulatory sequence (ISS)-based peanut immunotherapy demonstrated potent inhibition of harmful allergic responses and induction of therapeutic immune responses to pea...
Nov 8, 2004
BERKELEY, Calif., Nov 8, 2004 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported financial results for the third quarter 2004. Dynavax reported a net loss of $4.0 million for the quarter ended September 30, 2004, or $0.16 share, compared to a net loss of $4.1 million, or $2.30 per sh...
Nov 8, 2004
BERKELEY, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announced that Company executives will hold a conference call to discuss Dynavax's third quarter 2004 financial results on Monday, November 8, 2004 at 5:00 p.m. ET. A press release outlining third quarter 2004 results will be issued prior to the call...
Nov 1, 2004
100% Protective Response Sustained More Than One Year Later After Two-Dose Regimen of Dynavax's ISS-based VaccineBERKELEY, Calif., Nov 1, 2004 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) announced that data from a randomized, double-blind Phase 2 clinical trial of the company's prophylactic hepatitis B virus...
Oct 27, 2004
BERKELEY, Calif., Oct 27, 2004 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) announced that Company executives will hold a conference call to discuss Dynavax's third quarter 2004 financial results on Monday, November 8, 2004 at 5:00 p.m. ET. A press release outlining third quarter 2004 results will be issued prior...
Oct 20, 2004
BERKELEY, Calif., Oct 20, 2004 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) announced that safety and efficacy data from the company's Phase 2 clinical trial of its ISS-based Hepatitis B vaccine compared to GlaxoSmithKline's Engerix-B® vaccine will be presented in a late-breaker poster session at the 44th ...
Oct 18, 2004
BERKELEY, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company developing treatments for allergy, infectious`disease and chronic inflammatory disease, announced the establishment of a collaboration with Riken Institute for the development of novel cedar tree allergy therap...
Sep 27, 2004
BERKELEY, Calif., Sept. 27 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announced the appointment of Jane Green, Ph.D., as Vice President, Corporate Communications. Dr. Green will be responsible for the company's external and internal communications programs, including investor relations, public relations, media relation...
Sep 27, 2004
BERKELEY, Calif., Sept. 27 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announced today that Dino Dina, M.D., President and CEO, will present an overview of the company at the UBS Warburg Global Life Sciences Conference in New York City. Dr. Dina's presentation will be webcast live beginning at or about 11:30...
Sep 2, 2004
BERKELEY, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), today announced that it has completed enrollment and administered the first round of immunizations in a Phase II/III clinical trial of its hepatitis B (HBV) prophylactic vaccine candidate containing Dynavax's Immunostimulatory Sequence (I...
Aug 24, 2004
BERKELEY, Calif., Aug. 24 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced the appointment of Timothy Henn, to the position of Vice President, Finance and Administration. Mr. Henn comes to Dynavax from Incyte Corporation where he was most recently Senior Vice President, Finance and Corp...
Aug 5, 2004
BERKELEY, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases, today reported financial results for th...
Jul 28, 2004
Safety Confirmed; Biological Activity Indicates Reprogramming Of Immune System BERKELEY, Calif., July 28 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative produc
Jun 24, 2004
BERKELEY, Calif., Jun 24, 2004 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, today reported the successf...
Jun 22, 2004
BERKELEY, Calif., June 22 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, today announced that a Phase II/III cli...
Jun 7, 2004
BERKELEY, Calif., June 7 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, will hold its annual shareholders meetin...
May 20, 2004
BERKELEY, Calif., May 20 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, today announced that William J. Dawson, ...
May 19, 2004
BERKELEY, Calif., May 19 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, today announced that its Phase II/III cl...
May 4, 2004
BERKELEY, Calif., May 4 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, today reported financial results for the ...
Mar 29, 2004
BERKELEY, Calif., March 29 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, today reported financial results for t...
Mar 29, 2004
In the news release, Dynavax Reports 2003 Fourth Quarter and Full Year Results, issued earlier today by Dynavax Technologies Corporation (Nasdaq: DVAX) over PR Newswire, the "Additional paid-in capital" line in the "Condensed Consolidated Balance Sheets" financial table should read "12,762" rather than "2,762," as incorrectly transmitted...
Mar 25, 2004
BERKELEY, Calif., March 25 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, will hold an earnings conference call ...
Mar 8, 2004
BERKELEY, Calif., March 8 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today that Denise M. Gilbert, Ph.D., has joined its Board of Directors. Dr. Gilbert will also serve as chair of the Board's Audit Committee. With Dr. Gilbert's addition, Dynavax's Board of Directors increased to seven members....
Mar 4, 2004
BERKELEY, Calif., March 4 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced the appointment of D. Kevin Kwok, Pharm.D., to the position of vice president and chief business officer."We are excited to have Kevin join our team," said Dino Dina, M.D., president and chief executive officer of Dynavax. "...
Feb 25, 2004
BERKELEY, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today the start of a multi-site, phase II/III clinical trial to evaluate the safety and efficacy of its ragweed allergy immunotherapy product candidate, AIC. The two-year study will enroll 462 subjects at 30 allergy clinics throu...
Feb 24, 2004
BERKELEY, Calif., Feb. 24 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), today announced that the underwriters of its previously announced initial public offering of 6,000,000 shares of common stock have fully exercised their over-allotment option and acquired 900,000 common shares to cover over-allotments. To...
Feb 19, 2004
BERKELEY, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today that it has priced its initial public offering of 6,000,000 shares of its common stock at $7.50 per share, below the estimated range. Dynavax Technologies Corporation discovers, develops, and intends to commercial...
Feb 5, 2004
Berkeley, CA - February 5, 2004 - Dynavax Technologies Corporation announced today that it has entered into an agreement with UCB Pharma, the pharmaceuticals division of UCB Group, a publicly traded multi-national company based in Brussels, Belgium, in which Dynavax licensed the technology, know-how and preclinical and clinical data related to i...
Dec 18, 2003
Contact: Dino Dina, M.D. President and Chief Executive Officer Dynavax Technologies Corporation (510) 848-5100 Berkeley, CA - December 18, 2003 - Dynavax Technologies Corporation, a privately held biopharmaceutical company, announced today that the United States Patent and Trademark Office (USPTO) has de...
Nov 3, 2003
Contact: Dino Dina, M.D. President and Chief Executive Officer Dynavax Technologies Corporation (510) 848-5100 Berna Biotech Ltd Béatrice Keller Communications Manager communications@bernabiotech.com Phone +41 (0) 31 980 6522 Fax +41 (0) 31 980 6229 Ber...
Oct 24, 2003
Contact: Dino Dina, M.D. President and Chief Executive Officer Dynavax Technologies Corporation (510) 848-5100 Berkeley, CA - October 24, 2003 - Dynavax Technologies Corporation announced today that it has filed a registration statement with the Securities and Exchange Commission for the initial public o...
Aug 4, 2003
Contact: Dino Dina, M.D. President and Chief Executive Officer Dynavax Technologies Corporation (510) 848-5100 Berkeley, CA - August 4, 2003 - Dynavax Technologies Corporation today announced the appointment of Daniel Levitt, M.D., Ph.D., to the position of vice president and chief medical officer. He...
Sep 4, 2002
Contact: Dino Dina, M.D. President and Chief Executive Officer Dynavax Technologies Corporation (510) 848-5100 Berkeley, CA, September 4, 2002 - Dynavax Technologies, a privately held biopharmaceutical company, today announced it has initiated a Phase II clinical study to evaluate the abilit...
Aug 22, 2002
Contact: Dynavax Technologies Corporation Dino Dina, M.D. President and CEO 510-848-5100 Berkeley, CA -- August 22, 2002 - Dynavax Technologies Corporation today announced the appointment of William J. Dawson to the position of vice president, finance and operations, and chief financial o...
Apr 25, 2002
Contact: Andrew Gengos Chief Financial Officer Dynavax Technologies Corporation (510) 848-5100 Berkeley, CA, April 25, 2002 - Dynavax Technologies, a privately held biopharmaceutical company, today announced that it had raised $34.8 million in a private placement of its Series D Preferred St...
Dec 6, 2000
Contact: Dino Dina, M.D. President and CEO Dynavax Technologies Corporation (510) 848-5100 or (877) 848-5100 Berkeley, CA, December 6, 2000 - Dynavax Technologies Corporation today announced that it has named three new vice presidents, including Robert Lee Coffman, Ph.D., as Vice Preside...
= add release to Briefcase